

CITATION REPORT

List of articles citing

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

DOI: 10.1016/s0140-6736(11)60993-8
Lancet, The, 2011, 378, 771-84.

Source: <https://exaly.com/paper-pdf/50455066/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2259	Geriatric Pharmacotherapy Updates. 2011 , 9, 495-502		
2258	Progress in endocrine approaches to the treatment and prevention of breast cancer. 2011 , 70, 315-21		50
2257	Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot. 2011 , 55, 703-12		13
2256	Breast cancer misclassification: a major obstacle to treatment?. 2011 , 7, 615-8		
2255	The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer. 2011 , 18, 210-2		22
2254	Profile of V. Craig Jordan. 2011 , 108, 18876-8		
2253	A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ER β protein. 2012 , 33, 1089-97		40
2252	Tamoxifen and CYP2D6: a contradiction of data. 2012 , 17, 620-30		64
2251	Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. 2012 , 51, 781-9		16
2250	Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. 2012 , 23 Suppl 10, x219-27		46
2249	Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. 2012 , 30, 684-6		9
2248	Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. 2012 , 30, 686-9		24
2247	Changing concepts: Menopausal hormone therapy and breast cancer. 2012 , 104, 517-27		105
2246	Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. 2012 , 18, 5911-23		49
2245	Targeting adjuvant chemotherapy: a good idea that needs to be proven!. 2012 , 30, 1264-7		53
2244	A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. 2012 , 18, 4465-72		215
2243	Screening and breast cancer mortality--letter. 2012 , 21, 2275; author reply 2276-7		

2242	AACR Cancer Progress Report 2012. 2012 , 18, S1-100	20
2241	[Modern pharmacological therapy of breast cancer]. 2012 , 153, 56-65	2
2240	Effects of bone-targeted agents on cancer progression and mortality. 2012 , 104, 1059-67	157
2239	Cancer diagnosis: from dogs to DNA or from DNA to dogs?. 2012 , 50, 415-8	2
2238	Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. 2012 , 53, 1119-26	57
2237	Editorial: Targeted therapy for HER-2: personalized medicine for her, too. 2012 , 50, 1-4	9
2236	CXCR4-Blockade for Treatment of Breast Cancer. 2012 , 387-397	
2235	Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. 2012 , 9, 143-163	44
2234	Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue. 2012 , 7, e40092	62
2233	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. 2012 , 23, 2997-3006	189
2232	PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. 2012 , 53, 182-90	105
2231	Early breast cancer: diagnosis, treatment and survivorship. 2012 , 21, S4-8, S10	6
2230	Journal Club. 2012 , 7, 418-422	
2229	Adjuvantes Tamoxifen oder Trastuzumab macht Metastasen resistenter. 2012 , 15, 22-24	
2228	Translational Endocrinology & Metabolism: Breast Cancer Update. 2012 ,	
2227	Adapting to change and seeing the opportunities in breast cancer management. 2012 , 1, 1-3	
2226	Using modern molecular markers to tailor breast cancer treatment: a new era for personalized medicine. 2012 , 1, 105-108	2
2225	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. <i>Lancet, The</i> , 2012 , 379, 432-44	40 1372

2224	Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. 2012 , 30, 2601-8	321
2223	STAT1-deficient mice spontaneously develop estrogen receptor β -positive luminal mammary carcinomas. 2012 , 14, R16	122
2222	Breast density predicts endocrine treatment outcome in the adjuvant setting. 2012 , 14, 109	5
2221	Endokrine Therapie des frhen Mammakarzinoms. 2012 , 45, 603-607	
2220	Mammakarzinom. 2012 , 45, 623-632	
2219	Bouffes de chaleur, tamoxifne et cytochrome P450 2D6. 2012 , 14, 357-364	
2218	Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. 2012 , 134, 957-67	76
2217	Editorial. Preface. 2012 , 17, 189-90	
2216	Breast Cancer Primary Prevention: BERM-Mounting Existing Obstacles and Future Directions. 2012 , 23, 19-23	
2215	Is Breast Conservation Therapy Under Siege?. 2012 , 23, 128-131	1
2214	Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. 2012 , 15, 1167-75	8
2213	Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?. 2012 , 16 Suppl 1, S17-22	6
2212	6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer. 2012 , 139-167	1
2211	Expression of oestrogen receptor β and prognosis of colorectal cancer. 2012 , 107, 831-9	82
2210	Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors. 2012 , 18, 299-302	0
2209	SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?. 2012 , 12, 257	12
2208	Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. 2012 , 12, 458	45
2207	Cancer treatment according to BRCA1 and BRCA2 mutations. 2012 , 9, 520-8	56

2206	Breast Cancer: Blocking both driver and escape pathways improves outcomes. 2012 , 9, 133-4	10
2205	Biomarkers in the diagnosis of primary and recurrent breast cancer. 2012 , 6, 567-85	20
2204	Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. 2012 , 13, 1141-51	529
2203	Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. 2012 , 21, 769-78	16
2202	Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. 2012 , 21, 662-8	7
2201	[Radiotherapy for breast cancer: which strategy in 2012?]. 2012 , 16, 493-502	9
2200	Potential practice-changing therapies in breast cancer: The year in review. 2012 , 9, S40-S43	
2199	Nonsurgical adjunctive treatment and its effects on the axilla. 2012 , 36, 305-24	
2198	Fertility after breast cancer. 2012 , 73, 191-6	30
2197	Cancer biomarkers. 2012 , 6, 140-6	394
2196	Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. 2012 , 6, 222-36	39
2195	ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. 2012 , 6, 428-36	15
2194	Toremifene versus tamoxifen for advanced breast cancer. 2012 , CD008926	16
2193	Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. 2012 , 9, 529-41	57
2192	Recent results from the Early Breast Cancer Trialists' Collaborative Group. 2012 , 3, S20-S21	
2191	Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. 2012 , 21, 819-31	63
2190	Chromatin at the Intersection of Disease and Therapy. 2012 , 51-71	1
2189	BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. 2012 , 107, 947-55	55

2188	Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. 2012 , 14, R91	58
2187	Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. 2012 , 7, e36170	51
2186	17 β -Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer. 2012 , 7, e40568	13
2185	The molecular profile of luminal B breast cancer. 2012 , 6, 289-97	116
2184	2011 Publications of the Baylor Health Care System Medical and Scientific Staff. 2012 , 25, 188-204	
2183	Does Efficacy of Adjuvant Endocrine Therapy Correlate with Breast Cancer Patients? Ethnicity?. 2012 , 01,	
2182	Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. 2012 , 131, 1998-2007	23
2181	One life saved by four prevented recurrences? Update of the Early Breast Cancer Trialists confirms: postoperative radiotherapy improves survival after breast conserving surgery. 2012 , 188, 461-3	14
2180	Aktuelle Vernderungen der S3-Leitlinie Mammakarzinom. 2012 , 45, 443-447	
2179	Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. 2012 , 134, 267-76	39
2178	Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. 2012 , 134, 793-800	13
2177	Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. 2012 , 134, 459-78	383
2176	Opportunities for cost reduction of medical care: part 3. 2012 , 37, 888-96	4
2175	Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. 2012 , 70, 75-81	33
2174	Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. 2012 , 133, 595-606	63
2173	Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. 2012 , 133, 831-41	277
2172	Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. 2012 , 133, 367-73	78
2171	Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. 2012 , 133, 793-8	36

2170	Reply: Is the C677T Polymorphism in Methylenetetrahydrofolate Reductase Gene a Risk Factor for Diabetic Nephropathy or Diabetes Mellitus in a Chinese Population?. 2012 , 43, 168-169	1
2169	Implementation of TMA and digitalization in routine diagnostics of breast pathology. 2012 , 120, 341-7	12
2168	Scientific Surgery. 2012 , 99, 447-447	
2167	TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression. 2013 , 34, 3839-51	14
2166	Reliability of receptor assessment on core needle biopsy in breast cancer patients. 2013 , 34, 987-94	11
2165	Tamoxifen resistance: from bench to bedside. 2013 , 717, 47-57	66
2164	Interleukin-8 in breast cancer progression. 2013 , 33, 563-70	104
2163	A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. 2013 , 140, 219-32	140
2162	Luminal breast cancer: from biology to treatment. 2013 , 10, 494-506	123
2161	How can we improve survival from breast cancer in developing countries?. 2013 , 2, 179-183	7
2160	The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. 2013 , 71, 593-601	20
2159	CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. 2013 , 71, 301-6	10
2158	Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. 2013 , 73, 475-85	31
2157	Adjuvante Therapie mit Tamoxifen. 2013 , 19, 316-318	
2156	Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. 2013 , 119, 2494-502	13
2155	A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. 2013 , 133, 929-36	163
2154	Tamoxifen therapy for patients with breast cancer - Authors' reply. <i>Lancet, The</i> , 2013 , 381, 2078-9	40 2
2153	Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells. 2013 , 437, 463-8	6

2152	PET imaging of oestrogen receptors in patients with breast cancer. 2013 , 14, e465-e475	134
2151	Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. 2013 , 49, 3850-5	12
2150	The benefits and harms of breast cancer screening. <i>Lancet, The</i> , 2013 , 381, 802-3	40
2149	A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. 2013 , 7, 987-99	29
2148	Hypofractionation in the era of modulated radiotherapy (RT). 2013 , 22 Suppl 2, S129-36	6
2147	The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?. 2013 , 52, 1657-66	4
2146	Breast and Gynecological Cancers. 2013 ,	5
2145	HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. 2013 , 24, 2761-6	22
2144	Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. 2013 , 31, 2783-90	462
2143	Tranceformations: hypnosis in brain and body. 2013 , 30, 342-52	25
2142	Endocrine therapy: is the first generation of targeted drugs the last?. 2013 , 274, 144-52	34
2141	Integration of Gene Signatures and Genomic Data into Radiation Oncology Practice. 2013 , 29-46	
2140	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. 2013 , 15, R92	248
2139	Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics. 2013 , 140, 475-84	19
2138	Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. 2013 , 2, 356	13
2137	Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. 2013 , 140, 233-40	34
2136	Résistance aux traitements du cancer du sein (RPC 2013). 2013 , 15, 688-692	1
2135	Cancers du sein T1a,b N0 M0 (RPC 2013). 2013 , 15, 637-670	4

2134	A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation. 2013 , 142, 505-14		15
2133	A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score [®] assay in oestrogen receptor positive node negative breast cancer. 2013 , 49, 2469-75		46
2132	CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. 2013 , 14, 613-22		20
2131	Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. 2013 , 20, 1505-13		26
2130	Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. 2013 , 52, 82-90		13
2129	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. 2013 , 31, 203-9		376
2128	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet, The</i> , 2013 , 381, 805-16	40	1293
2127	Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. 2013 , 137, 397-406		75
2126	What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?. 2013 , 31, 1391-7		12
2125	How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?. 2013 , 15, 101		3
2124	Advances in Targeted Therapy for the Prevention of Breast Cancer. 2013 , 24, 309-314		
2123	Multidisciplinary care of patients with early-stage breast cancer. 2013 , 22, 299-317		3
2122	Special considerations in early-stage breast cancer patients and survivors. 2013 , 40, 573-82		2
2121	The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. 2013 , 130, 127-31		83
2120	New developments and future directions in systemic therapy. 2013 , 25, 117-26		9
2119	Extended adjuvant tamoxifen for breast cancer--a new era?. <i>Lancet, The</i> , 2013 , 381, 782-3	40	12
2118	Tackling the diversity of triple-negative breast cancer. 2013 , 19, 6380-8		120
2117	A potential role for sex hormone receptor antagonists in treatment of malignant salivary gland tumours, as compared to breast cancer: A review of literature. 2013 , 10, 75-85		5

2116	Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. 2013 , 11, 3-22	3
2115	Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. 2013 , 22 Suppl 2, S180-3	19
2114	Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. 2013 , 49, 2294-302	140
2113	36th Annual San Antonio Breast Cancer Symposium: resumen de los conceptos clínicos más relevantes. 2013 , 26, 65-72	
2112	Long-term outcome of breast cancer patients treated with radiofrequency ablation. 2013 , 24, 164-165	
2111	Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. 2013 , 86, 23-32	31
2110	Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis. 2013 , 22, 643-9	3
2109	P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. 2013 , 88, 284-92	24
2108	Translating metastasis-related biomarkers to the clinic--progress and pitfalls. 2013 , 10, 169-79	35
2107	Biomarkers for the clinical management of breast cancer: international perspective. 2013 , 133, 1-13	118
2106	Comprehensive analysis of PTEN status in breast carcinomas. 2013 , 133, 323-34	36
2105	Estrogen receptor β is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. 2013 , 139, 71-80	55
2104	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. 2013 , 139, 39-49	41
2103	Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. 2013 , 10, 289-301	158
2102	Pharmacogenomics of breast cancer therapy: an update. 2013 , 139, 1-11	28
2101	Stromal cells in tumor microenvironment and breast cancer. 2013 , 32, 303-15	438
2100	Companion biomarkers: paving the pathway to personalized treatment for cancer. 2013 , 59, 1447-56	37
2099	Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. 2013 , 56, 4611-8	39

2098	Changing concepts of hormone receptor-positive advanced breast cancer therapy. 2013 , 13, 159-66	22
2097	Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?. 2013 , 13, 167-72	18
2096	Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story. 2013 , 93, 1-49	12
2095	Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. 2013 , 140, 93-104	41
2094	Breast and Gynecologic Cancer Prevention in Low-Resource Countries. 2013 , 169-188	1
2093	Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study. 2013 , 20, 455-62	23
2092	Pharmacogenomics of endocrine therapy in breast cancer. 2013 , 58, 306-12	15
2091	Molecular imaging for monitoring treatment response in breast cancer patients. 2013 , 717, 2-11	11
2090	Adjuvant endocrine therapy for the surgeon: options, side effects, and their management. 2013 , 20, 3188-93	7
2089	A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. 2013 , 24, 47-53	29
2088	Tumour heterogeneity in the clinic. 2013 , 501, 355-64	770
2087	MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. 2013 , 15, 335-42	31
2086	AACR Cancer Progress Report 2013. 2013 , 19, S4-98	47
2085	Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. 2013 , 31, 4571-3	2
2084	[Evolving strategies over time for treatment of breast cancer]. 2013 , 100, 857-63	1
2083	Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2013 , 10, 164-192	18
2082	Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. 2013 , 73, 556-583	41
2081	Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. 2013 , 54, 1697-702	54

2080	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. 2013 , 24, 2715-24	84
2079	Targeted therapy for breast cancer prevention. 2013 , 3, 250	89
2078	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. 2013 , 7, 1-19	8
2077	Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer?. 2013 , 20, 191-2	
2076	RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. 2013 , 24, 632-9	18
2075	HER2 and breast cancer stem cells: more than meets the eye. 2013 , 73, 3489-93	96
2074	Relationship of oestrogen receptor status to depressive symptoms and quality of life in breast cancer patients. 2013 , 25, 283-8	1
2073	Tamoxifen. 2013 ,	10
2072	Biomarkers in the management of breast cancer: great expectations, hard times. 2013 , 21, 481-4	3
2071	Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast. 2013 , 21, 90-3	2
2070	Advances in the treatment of luminal breast cancer. 2013 , 25, 49-54	13
2069	Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. 2013 , 110, E1490-9	120
2068	Why your preferred targeted drugs may become unaffordable. 2013 , 73, 5849-51	7
2067	Approaches for assessing and discovering protein interactions in cancer. 2013 , 11, 1295-302	7
2066	G protein-coupled estrogen receptor is apoptotic and correlates with increased distant disease-free survival of estrogen receptor-positive breast cancer patients. 2013 , 19, 1681-92	31
2065	Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. 2013 , 6, 1249-59	113
2064	Expression of both estrogen receptor-beta 1 (ER- β 1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER- α) negative early breast cancer (EBC). 2013 , 24, 1986-93	37
2063	Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. 2013 , 15, R119	37

2062	Black-white differences in breast cancer outcomes among older Medicare beneficiaries: does systemic treatment matter?. 2013 , 310, 376-7	12
2061	CYP2D6 genotyping and the use of tamoxifen in breast cancer. 2013 , 105, 1267-9	15
2060	Treatment-emergent effects may predict benefit from endocrine therapy. 2013 , 31, 2233-5	3
2059	German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. 2013 , 31, 3531-9	72
2058	Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. 2013 , 11, 1269-78	35
2057	Biomarker discordance: why it occurs and why it is important. 2012 , 12, 219-30	1
2056	Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. 2013 , 52, 91-101	18
2055	Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis. 2013 , 2, 228-42	20
2054	Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer. 2012 , 12, 241-50	4
2053	Factors predicting late recurrence for estrogen receptor-positive breast cancer. 2013 , 105, 1504-11	156
2052	Addressing overtreatment in breast cancer: The doctors' dilemma. 2013 , 119, 3584-8	33
2051	The challenges of individualized care for older patients with localized breast cancer. 2013 , 13, 963-73	
2050	Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. 2013 , 24, 2897-902	38
2049	The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. 2013 , 109, 1172-80	69
2048	An unmet need: tailoring extended adjuvant endocrine therapy. 2013 , 109, 2951-3	3
2047	Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. 2013 , 108, 1515-24	171
2046	Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. 2013 , 108, 179-82	189
2045	A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial. 2013 , 24, 2284-91	4

2044	Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. 2013 , 15, R68	92
2043	miR-342 is associated with estrogen receptor- α expression and response to tamoxifen in breast cancer. 2013 , 5, 813-818	57
2042	Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. 2013 , 8, 110-20	6
2041	Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancer. 2013 , 85, 100-10	42
2040	Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment. 2013 , 15, R93	9
2039	ENDOCRINE PREVENTION OF BREAST CANCER. 2013 , 361-390	
2038	Contralateral prophylactic mastectomy: perceptions versus reality. 2013 , 159, 428-9	5
2037	Conference Scene: Highlights from the San Antonio Breast Cancer Symposium 2012. 2013 , 2, 109-113	
2036	Molekulares Profil im Visier. 2013 , 16, 38-41	
2035	Molekulares Profil im Visier. 2013 , 18, 21-25	
2034	Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. 2013 , 20, 721-6	7
2033	Journal Club. 2013 , 8, 84-87	
2032	The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment. 2013 , 1, 65-71	
2031	CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. 2013 , 8, e76648	34
2030	A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status. 2013 , 8, e82144	9
2029	Potential reduction of contralateral second breast-cancer risks by prophylactic mammary irradiation: validation in a breast-cancer-prone mouse model. 2013 , 8, e85795	11
2028	The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. 2013 , 8, 135-55	221
2027	Systemic cancer therapy: achievements and challenges that lie ahead. 2013 , 4, 57	125

2026	Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. 2013 , 4, 68	75
2025	Next-generation sequencing of disseminated tumor cells. 2013 , 3, 320	29
2024	Ten years of progress against breast cancer: a partnership of basic and clinical/translational science. 2013 , 11, 132-6	
2023	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. 2013 , 603-615	
2022	Cancer log-kill revisited. 2014 , 3-7	9
2021	Selective estrogen receptor modulators: tissue specificity and clinical utility. 2014 , 9, 1437-52	123
2020	Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. 2014 , 3, 521-36	6
2019	PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs. 2014 , 7, 1723-31	12
2018	Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. 2014 , 9, e108405	25
2017	Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. 2014 , 2014, 901371	8
2016	Analysis of predictive factors for lung injury after forward-planned intensity-modulated radiotherapy in whole breast irradiation. 2014 , 17, 69-75	5
2015	Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study. 2014 , 5, 151-5	26
2014	Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report. 2014 , 81, 333-6	1
2013	[Factors influencing quality of life in patients with breast cancer on hormone therapy]. 2014 , 44, 108-17	15
2012	The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?. 2014 , e16-24	6
2011	Fifty years of progress in radiation therapy for breast cancer. 2014 , 21-5	10
2010	Subtyping of breast cancer using reverse phase protein arrays. 2014 , 11, 757-70	13
2009	Role of MTA2 in human cancer. 2014 , 33, 921-8	36

2008	Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling. 2014 , 14, 735	36
2007	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. 2014 , 148, 143-51	34
2006	Adjuvante endokrine Therapie des Mammakarzinoms [Ein Update. 2014 , 9, 6-11	
2005	The effect of tamoxifen on expression of ER, PR, Cerb-B2, and ki-67 in C3H mice spontaneous breast cancer model and the relation with chemotherapeutic effect. 2014 , 70, 1875-9	2
2004	Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. 2014 , 16, 452	18
2003	Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. 2014 , 106,	12
2002	Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. 2014 , 32, 99-104	17
2001	Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: balance of breast risks and endometrial benefits--systematic review of literature. 2014 , 21, 423-31	22
2000	Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. 2014 , 16, 1047-58	61
1999	Do breast cups improve breast cancer dosimetry? A comparative study for patients with large or pendulous breasts. 2014 , 53, 795-801	10
1998	Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. 2014 , 11, e1001720	64
1997	Harveian Oration 2012: Halving premature death. 2014 , 14, 643-57	3
1996	Incidence of metachronous contralateral breast cancer in Denmark 1978-2009. 2014 , 43, 1855-64	24
1995	Survival analysis of breast cancer subtypes in patients with spinal metastases. 2014 , 39, 1620-7	17
1994	Guideline conformity treatment in young women with early-onset breast cancer in Germany. 2014 , 9, 349-54	3
1993	GPER Function in Breast Cancer: An Overview. 2014 , 5, 66	71
1992	Die Therapieplanung junger Frauen mit Mammakarzinom [Eine besondere Herausforderung. 2014 , 11, 85-90	
1991	Tamoxifen [Ein polarisierender Wirkstoff in Zeiten zunehmender Personalisierung der Arzneimitteltherapie. 2014 , 46, 16-20	

1990	[Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey]. 2014 , 101, 918-24	4
1989	Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy. 2014 , 23, 754-62	16
1988	Estrogen and progesterone receptors in breast cancer. 2014 , 10, 2293-301	77
1987	Review of psychotherapeutic interventions on depression in cancer patients and their impact on disease progression. 2014 , 26, 31-43	45
1986	The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. 2014 , 7, 698-707	55
1985	Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer. 2014 , 20, 46-52	3
1984	Heterogeneity of breast cancer clinical characteristics and outcome in US black women--effect of place of birth. 2014 , 20, 489-95	2
1983	Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. 2014 , 106,	27
1982	Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. 2014 , 25, 2251-2260	58
1981	Significance of ER β ,HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor. 2014 , 26, 390-403	9
1980	Reviews of individual patient data (IPD) are useful for geriatrics: an overview of available IPD reviews. 2014 , 62, 1133-8	2
1979	Hormone therapy in premenopausal women with early-stage breast cancer. 2014 , 371, 175-6	8
1978	[Legal value of the recommendations of good practice: example for breast cancer hormonotherapy]. 2014 , 101, 283-94	
1977	The efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer. 2014 , 6, 36-42	1
1976	NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. 2014 , 148, 581-90	62
1975	Estrogen receptor, progesterone receptor, interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations. 2014 , 14, 733	11
1974	Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study. 2014 , 14, 817	13
1973	Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy. 2014 , 12, 335	35

1972	Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. 2014 , 20, 2485-94	34
1971	The renaissance of endocrine therapy in breast cancer. 2014 , 26, 41-7	20
1970	Estrogen and Progesterone Receptor Assessment. 2014 , 19, 265-268	
1969	Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. 2014 , 21, R235-46	104
1968	Predicting the chance of relapse after tamoxifen treatment in breast cancer. 2014 , 8, 77-9	1
1967	Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence. 2014 , 6, 52-68	46
1966	Screening mammography--early detection or over-diagnosis? Contribution from Australian data. 2014 , 17 Suppl 2, 66-72	8
1965	Contralateral prophylactic mastectomy: are we overtreating patients?. 2014 , 14, 491-4	5
1964	Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. 2014 , 23, 725-34	43
1963	The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. 2014 , 20, 1298-305	144
1962	No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. 2014 , 148, 135-42	8
1961	Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?. 2014 , 19, 592-601	35
1960	Hormone Responsive Cancers. 2014 , 651-698.e14	
1959	Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells. 2014 , 14, 1	18
1958	Status of adjuvant endocrine therapy for breast cancer. 2014 , 16, 206	54
1957	Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. 2014 , 16, R62	51
1956	Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. 2014 , 32, 2318-27	60
1955	Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. 2014 , 32, 2951-8	85

1954	Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. 2014 , 25, 623-628	31
1953	Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer. 2014 , 67, 966-72	7
1952	OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. 2014 , 8, 1196-207	17
1951	Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. 2014 , 50, 1412-21	19
1950	Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer. 2014 , 143, 160-73	29
1949	RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. 2014 , 71, 1549	17
1948	Minding the body: psychotherapy and cancer survival. 2014 , 19, 465-85	27
1947	Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. 2014 , 143, 403-9	64
1946	Symptoms of endocrine treatment and outcome in the BIG 1-98 study. 2014 , 143, 159-69	29
1945	The use of radiotherapy for early breast cancer in woman at different ages. 2014 , 16, 680-5	5
1944	Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. 2014 , 145, 61-71	49
1943	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet, The</i> , 2014 , 383, 2127-35	40 1237
1942	Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. 2014 , 144, 249-61	37
1941	Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. 2014 , 37, 107-18	13
1940	Expression profiling of breast cancer patients treated with tamoxifen: prognostic or predictive significance. 2014 , 31, 896	7
1939	How do I recommend extended adjuvant hormonal therapy?. 2014 , 15, 55-62	3
1938	Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. 2014 , 144, 133-42	18
1937	Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery. 2014 , 9, 36	16

1936	Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. 2014 , 143, 477-83	35
1935	Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. 2014 , 44, 1841-6	6
1934	LRH-1 governs vital transcriptional programs in endocrine-sensitive and -resistant breast cancer cells. 2014 , 74, 2015-25	37
1933	Precision treatment for cancer: role of prognostic and predictive markers. 2014 , 51, 30-45	22
1932	Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. 2014 , 382, 683-694	40
1931	p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. 2014 , 105, 81-8	49
1930	E14. New techniques in radiotherapy of breast cancer. 2014 , 50, S28-S29	
1929	ERK/MAPK regulates ER α expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer. 2014 , 281, 2431-42	45
1928	Low concordance of biomarkers in histopathological and cytological material from breast cancer. 2014 , 64, 971-80	14
1927	First international consensus guidelines for breast cancer in young women (BCY1). 2014 , 23, 209-20	108
1926	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 2014 , 15, 681-700	40
1925	MicroRNA in Development and in the Progression of Cancer. 2014 ,	6
1924	Which threshold for ER positivity? a retrospective study based on 9639 patients. 2014 , 25, 1004-11	122
1923	Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. 2014 , 14, 26-38	105
1922	Breast cancer: current and future endocrine therapies. 2014 , 382, 695-723	69
1921	Breast Cancer. 2014 ,	3
1920	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. 2014 , 15, 156-63	148
1919	The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?. 2014 , 16, 358	8

1918	Tracking progesterone receptor-mediated actions in breast cancer. 2014 , 142, 114-25	51
1917	Co-targeting estrogen receptor and HER2 pathways in breast cancer. 2014 , 23, 2-9	25
1916	Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics. 2014 , 180, 705-17	17
1915	IN10 What's new in endocrine therapy in young women. 2014 , 23, S5	
1914	IN8 Neoadjuvant therapy for young women with breast cancer. 2014 , 23, S4-S5	
1913	IN9 The management of triple negative breast cancer. 2014 , 23, S5	
1912	IN11 Oncobrain: is it real and what can be done?. 2014 , 23, S5-S6	
1911	Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. 2014 , 15, 49-60	31
1910	Oestrogen receptors α and β have divergent roles in breast cancer survival and lymph node metastasis. 2014 , 111, 918-26	18
1909	Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. 2014 , 102, 488-495.e3	75
1908	Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. 2014 , 171, 5624-35	20
1907	Aromatase inhibitors in the breast cancer clinic: focus on exemestane. 2014 , 21, R31-49	40
1906	Estradiol affects extracellular leptin:adiponectin ratio in human breast tissue in vivo. 2014 , 99, 3460-7	25
1905	The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. 2014 , 90, 3-12	21
1904	An update on the medical management of breast cancer. 2014 , 348, g3608	46
1903	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. 2014 , 147, 295-309	9
1902	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. 2014 , 10, 107-22	60
1901	Risk of contralateral breast cancer after tamoxifen use among Danish women. 2014 , 24, 843-8	13

1900	Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. 2014 , 8, 521-31	36
1899	Lost in translation: can we afford to miss the trees for the forest?. 2014 , 5, 203-6	1
1898	ERβ splice variant expression in four large cohorts of human breast cancer patient tumors. 2014 , 146, 657-67	36
1897	Selective estrogen-induced apoptosis in breast cancer. 2014 , 90, 60-70	10
1896	A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. 2014 , 50, 2866-76	38
1895	Multimodale Therapie des nicht metastasierten Mammakarzinoms. 2014 , 20, 379-394	1
1894	Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. 2014 , 145, 725-34	57
1893	Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. 2014 , 145, 155-64	13
1892	Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. 2014 , 146, 137-44	30
1891	Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. 2014 , 164, 620-4	20
1890	Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. 2014 , 65, 508-16	14
1889	Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells. 2014 , 57, 4569-83	16
1888	Testing the treatment effect on competing causes of death in oncology clinical trials. 2014 , 14, 72	5
1887	Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. 2014 , 14, 172	40
1886	Past, present, and future challenges in breast cancer treatment. 2014 , 32, 1979-86	142
1885	Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. 2014 , 90, 44-52	22
1884	Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. 2014 , 106,	68
1883	Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. 2014 , 50, 2877-86	12

1882	The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?. 2014 , 32, 347-54	31
1881	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. 2014 , 371, 107-18	500
1880	Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action. 2014 , 14, 75-84	24
1879	Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. 2014 , 95, 98-103	38
1878	1 α ,25-dihydroxyvitamin D3 inhibits cell growth and NF κ B signaling in tamoxifen-resistant breast cancer cells. 2014 , 85, 30-5	30
1877	Use of SERMs for treatment in postmenopausal women. 2014 , 142, 142-54	98
1876	Personalized therapy for breast cancer. 2014 , 86, 62-7	39
1875	Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy. 2014 , 202, 912-21	8
1874	Metabolism of Human Diseases. 2014 ,	4
1873	Drug resistance to targeted therapies: dJlvu all over again. 2014 , 8, 1067-83	137
1872	Current knowledge and future research directions in treatment-related second primary malignancies. 2014 , 12, 5-17	39
1871	T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. 2014 , 344, 90-100	19
1870	Breast cancer version 3.2014. 2014 , 12, 542-90	139
1869	CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. 2014 , 95, 216-27	131
1868	Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor β . 2014 , 45, 2167-75	12
1867	Outcomes of adjuvant endocrine therapy and hormone receptor status change following neoadjuvant chemotherapy in breast cancer patients. 2014 , 29, e380-6	1
1866	Adjuvant hormonal therapy in young breast cancer patients. 2014 , 3, 1-4	2
1865	PG 1.02 Clinical utility of genetic signatures in selecting adjuvant treatment: risk stratification in early versus late recurrences. 2015 , 24, S2	

- 1864 Prognosefaktoren für Lokal-, lokoregionäre- und systemische Rezidive beim frühen Mammakarzinom. **2015**, 12, 209-217
- 1863 Die richtige Therapie für die richtige Patientin [personalisierte Behandlung des Mammakarzinoms. **2015**, 12, 192-200
- 1862 New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. **2015**, 46, 1481-90 13
- 1861 Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes. **2015**, 23, 677-81 7
- 1860 Quantifying intra- and inter-fractional motion in breast radiotherapy. **2015**, 62, 40-6 12
- 1859 The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. **2015**, 278, 545-70 38
- 1858 Tumor Heterogeneity in Breast Cancer. **2015**, 22, 294-302 8
- 1857 Cancer Pharmacogenomics. **2015**, 1, 164-191
- 1856 miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. **2015**, 5, 13170 57
- 1855 Targeted Therapy for Breast Cancer. **2015**, 190-192
- 1854 The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer. **2015**, 10, 312-5 9
- 1853 SEOM clinical guidelines in early-stage breast cancer 2015. **2015**, 17, 939-45 14
- 1852 Hypofractionated irradiation in elderly patients with breast cancer after breast conserving surgery and mastectomy : Analysis of 205 cases. **2015**, 10, 161 15
- 1851 Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. **2015**, 13, 254 12
- 1850 Prädiktive Faktoren bei gynäkologischen Tumoren. **2015**, 48, 865-870 1
- 1849 High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. **2015**, 121, 3422-7 50
- 1848 The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care. **2015**, 13, 223 1
- 1847 How should individual participant data (IPD) from publicly funded clinical trials be shared?. **2015**, 13, 298 36

1846	Poly(ADP-ribose) polymerase as a novel regulator of 17 β -estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis. 2015 , 13, 233	10
1845	Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden. 2015 , 13, 15	10
1844	In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. 2015 , 80, 1122-30	30
1843	Exemestane for breast cancer risk reduction. 2015 , 4, 159-164	
1842	Hormones in cancer. 24-41	
1841	Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem. 2015 , 18, 207-17	24
1840	Targeted pathways in breast cancer: molecular and protein markers guiding therapeutic decisions. 2014 , 7, 4-21	21
1839	Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. 2015 , 7, 181-7	18
1838	Proportion and clinical outcomes of postoperative radiotherapy omission after breast-conserving surgery in women with breast cancer. 2015 , 18, 50-6	4
1837	A Dosimetric Comparative Analysis of TomoDirect and Three-Dimensional Conformal Radiotherapy in Early Breast Cancer. 2015 , 18, 57-62	6
1836	Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?. 2015 , 6, 3519-30	63
1835	Mechanistic Progress of Estrogen-induced Apoptosis in Estrogen-deprived Breast Cancer Cells. 2015 , 06,	
1834	SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment. 2015 , 10, e0118346	20
1833	Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. 2015 , 10, e0132449	33
1832	Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. 2015 , 8, 1433-41	16
1831	The Prescription Pattern of Chinese Herbal Products Containing Ginseng among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study. 2015 , 2015, 385204	8
1830	. 2015 ,	2
1829	Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. 2015 , 6, 12234-47	78

1828	Current medical treatment of estrogen receptor-positive breast cancer. 2015 , 6, 231-9	79
1827	Evaluation of CYP2D6 enzyme activity using a ¹³ C-dextromethorphan breath test in women receiving adjuvant tamoxifen. 2015 , 25, 157-63	10
1826	Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. 2015 , 34, 1919-27	50
1825	Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach. 2015 , 31, 146-55	23
1824	Synthesis of targeted dibenzo[b,f]thiepinines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity. 2015 , 99, 113-24	25
1823	Perceptions of Contralateral Breast Cancer Risk: A Prospective, Longitudinal Study. 2015 , 22, 3846-52	19
1822	Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies. 2015 , 128, 153-80	11
1821	Managing Breast Cancer in Young Women. 2015 , 11-27	
1820	Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. 2015 , 15, 241-4	17
1819	Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence. 2015 , 41, 271-6	28
1818	Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. 2015 , 152, 57-65	13
1817	Assessment of estrogen receptor expression in epithelial ovarian cancer patients using ¹⁶ β- ¹⁸ F-fluoro- ¹⁷ β-estradiol PET/CT. 2015 , 56, 50-5	34
1816	Role of the bradykinin B2 receptor in a rat model of local heart irradiation. 2015 , 91, 634-42	1
1815	A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. 2015 , 13, 126	18
1814	ERR1 target genes are poor prognostic factors in Tamoxifen-treated breast cancer. 2015 , 34, 45	27
1813	Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy. 2015 , 21, 4086-4096	10
1812	Hormonal therapy in oncology: a primer for the radiologist. 2015 , 204, W620-30	16
1811	Breast Cancer in General Population. 2015 , 331-351	

1810	The Role of Adjuvant Systemic Therapy. 2015 , 403-429	
1809	Adjuvant Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer in Premenopausal Patient: Understanding the Data. 2015 , 7, 183-189	
1808	Aurora A and Mcl-1: new potential treatment targets in antiestrogen-resistant breast cancer.. 2021 , 8, 998898	
1807	Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. 2015 , 15, 890	55
1806	A Review on Breast Cancer Care in Africa. 2015 , 10, 364-70	33
1805	Reply to L. Antolini et al. 2015 , 33, 3978-9	
1804	Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer. 2015 , 20, 598-604	24
1803	Unemployment, public-sector health-care spending and breast cancer mortality in the European Union: 1990-2009. 2015 , 25, 330-5	13
1802	The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. 2015 , 107,	27
1801	Effects of Tamoxifen and Other SERMs in the Endometrium and Follow-Up of Patients. 2015 , 437-441	
1800	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. 2015 , 21, 2763-70	29
1799	Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. 2015 , 154, 533-41	29
1798	Survival time according to the year of recurrence and subtype in recurrent breast cancer. 2015 , 24, 588-93	11
1797	Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells. 2015 , 46, 2047-56	14
1796	Association of human epidermal growth factor receptor 2 status with ipsilateral breast tumor recurrence and resistance to endocrine therapy. 2015 , 3, 843-846	0
1795	Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. 2015 , 4, 825	13
1794	Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer. 2015 , 33, 1064-70	28
1793	HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen. 2015 , 47, 1311-20	5

1792	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. 2015 , 16, 67-75	270
1791	Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells. 2015 , 34, 3871-80	20
1790	Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer. 2015 , 24, 421-31	23
1789	Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. 2015 , 41, 289-99	76
1788	IBIS-I tamoxifen update: maturity brings questions. 2015 , 16, 7-9	31
1787	Tamoxifen resistance: from cell culture experiments towards novel biomarkers. 2015 , 211, 189-97	47
1786	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. 2015 , 26, 81-88	57
1785	The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. 2015 , 22, R1-31	93
1784	Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. 2015 , 24, 24-31	10
1783	Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?. 2015 , 24, 62-7	15
1782	The future of breast cancer systemic therapy: the next 10 years. 2015 , 93, 119-25	17
1781	Germline oncopharmacogenetics, a promising field in cancer therapy. 2015 , 38, 65-89	7
1780	Estrogen receptors β and γ are associated with distinct responses of estrogen receptor α -positive breast carcinoma to adjuvant endocrine therapy. 2015 , 358, 37-42	6
1779	Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. 2015 , 15, e131-7	21
1778	The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer. 2015 , 22, 59-65	4
1777	The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy. 2015 , 112, 636-43	36
1776	Intraoperative Radiotherapy: Is it Ready for Prime Time?. 2015 , 7, 15-21	
1775	Unique aspects of caring for young breast cancer patients. 2015 , 17, 1	16

1774	Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. 2015 , 150, 439-45		18
1773	Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?. 2015 , 33, 823-8		9
1772	Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. 2015 , 16, 287-96		22
1771	A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. 2015 , 34, 4199-210		38
1770	Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. 2015 , 22, S82-94		25
1769	Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. 2015 , 22, S67-81		39
1768	The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. 2015 , 418 Pt 3, 245-63		20
1767	Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. 2015 , 152, 377-87		52
1766	Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?. 2015 , 15, 169-70		
1765	In Regard to Vaidya et'al. 2015 , 92, 952-953		3
1764	Adjuvant Endocrine Therapy and Bone Health in Breast Cancer. 2015 , 13, 263-73		3
1763	Gene-Expression-Based Predictors for Breast Cancer. 2015 , 22, 3418-32		19
1762	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet, The</i> , 2015 , 386, 1341-1352	40	748
1761	Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. <i>Lancet, The</i> , 2015 , 386, 1353-1361	40	447
1760	New insights into endocrine therapy for young women with breast cancer. 2015 , 11, 343-54		2
1759	Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale. 2015 , 79, 254-67		10
1758	Radiotherapy Induces Development of Fragmented QRS in Patients with Breast Cancer. 2015 , 10, 277-80		9
1757	Why have breast cancer mortality rates declined?. 2015 , 5, 8-17		80

1756	Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: A systematic review and meta-analysis. 2015 , 98, 1524-1524	38
1755	Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. 2015 , 22, S95-S113	31
1754	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. 2015 , 33, 2353-60	135
1753	mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. 2015 , 367, 76-87	36
1752	Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. 2015 , 373, 317-27	639
1751	IVF for fertility preservation in breast cancer patients--efficacy and safety issues. 2015 , 32, 1171-8	36
1750	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. 2015 , 21, 751-9	521
1749	A review on metastatic breast cancer in Iran. 2015 , 5, 429-433	18
1748	Biomarkers in Breast Cancer: Where Are We and Where Are We Going?. 2015 , 71, 1-23	60
1747	A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers. 2015 , 139, 612-7	28
1746	CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer. 2015 , 21, 3794-805	131
1745	Emotional Freedom Techniques (EFT) to reduce the side effects associated with tamoxifen and aromatase inhibitor use in women with breast cancer: A service evaluation. 2015 , 7, 136-142	4
1744	¹⁶ [¹⁸ F]-fluoro- ¹⁷ βestradiol ([¹⁸ F]FES): A biomarker for imaging oestrogen receptor expression with positron emission tomography (PET). 2015 , 39, 64-70	3
1743	Mechanisms of aromatase inhibitor resistance. 2015 , 15, 261-75	233
1742	Changing Surgical Trends in Young Patients with Early Stage Breast Cancer, 2003 to 2010: A Report from the National Cancer Data Base: Pesce CE, Liederbach E, Czechura T, et al (NorthShore Univ HealthSystem, Evanston, IL) J Am Coll Surg 219:19-30, 2014. 2015 , 26, 58-60	
1741	Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients. 2015 , 24, 224-9	9
1740	The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue. 2015 , 81, 42-5	14
1739	PG 1.01 Surgical management of early breast cancer 2015. 2015 , 24, S1-S2	

1738	miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ER-positive breast cancer. 2015 , 589, 812-21	38
1737	Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study. 2015 , 182, 44-9	17
1736	The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry. 2015 , 149, 537-46	13
1735	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. 2015 , 14, 383-91	23
1734	Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. 2015 , 23, 3115-30	30
1733	Lymph node status in inflammatory breast cancer. 2015 , 151, 113-20	15
1732	Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. 2015 , 26, 45-56	13
1731	Breast cancer under age 40: a different approach. 2015 , 16, 16	43
1730	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. 2015 , 24, 201-7	76
1729	TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. 2015 , 22, 465-79	34
1728	In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor. 2015 , 17, 27	18
1727	Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. 2015 , 22, 3861-5	5
1726	High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. 2015 , 15, 204-11	25
1725	Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. 2015 , 54, 797-810	44
1724	The Outpatient Breast Clinic. 2015 ,	
1723	Resistance to Aromatase Inhibitors in Breast Cancer. 2015 ,	1
1722	Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria. 2015 , 26, 1043-1044	7
1721	Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. 2015 , 150, 231-42	33

1720	A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1). 2015 , 21, 9185-97	38
1719	Indications for prognostic gene expression profiling in early breast cancer. 2015 , 16, 23	24
1718	Update on breast cancer risk prediction and prevention. 2015 , 27, 92-7	22
1717	The novel role of miRNAs for tamoxifen resistance in human breast cancer. 2015 , 72, 2575-84	17
1716	Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. 2015 , 107, djv075	27
1715	Tamoxifen (selective estrogen-receptor modulators) and aromatase inhibitors as potential perioperative thrombotic risk factors in free flap breast reconstruction. 2015 , 135, 670e-679e	20
1714	Targeting thyroid hormone receptor beta in triple-negative breast cancer. 2015 , 150, 535-45	26
1713	Landscape of neoadjuvant therapy for breast cancer. 2015 , 22, 1408-15	36
1712	Endocrine therapy in cancer care. 2015 , 33, 122-126	
1711	Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer. 2015 , 75, 710-718	13
1710	The Right Treatment for the Right Patient - Personalised Treatment of Breast Cancer. 2015 , 75, 683-691	12
1709	CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. 2015 , 153, 583-90	46
1708	Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. 2015 , 7, 291-6	21
1707	The changing role of ER in endocrine resistance. 2015 , 24 Suppl 2, S60-6	62
1706	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. 2015 , 373, 2005-14	865
1705	A historic and scientific review of breast cancer: The next global healthcare challenge. 2015 , 131 Suppl 1, S36-9	62
1704	Anti-proliferative activities of flavone-estradiol Stille-coupling adducts and of indanone-based compounds obtained by SnCl ₄ /Zn-catalysed McMurry cross-coupling reactions. 2015 , 5, 83512-83521	4
1703	The role of steroid hormones in breast cancer stem cells. 2015 , 22, T177-86	23

1702	Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. 2015 , 12, 1968-77	129
1701	Five-year risk of interval-invasive second breast cancer. 2015 , 107,	26
1700	Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. 2015 , 1, 296-305	141
1699	Risk Factors, Diagnosis, and Staging of Endometrial Cancer. 2015 , 53-63	
1698	Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. 2015 , 26, 2363-6	14
1697	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. 2015 , 154, 275-86	30
1696	[Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation?]. 2015 , 43, 800-5	2
1695	Biological markers of invasive breast cancer. 2016 , 46, 99-105	19
1694	Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. 2015 , 141, 2229-40	10
1693	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. 2015 , 152, 247-52	16
1692	Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. 2015 , 152, 627-36	30
1691	Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. 2015 , 24, 403-8	13
1690	Precision Molecular Pathology of Breast Cancer. 2015 ,	3
1689	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. 2015 , 75, 1311-21	3
1688	Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer. 2015 , 152, 209-216	11
1687	Progress in adjuvant chemotherapy for breast cancer: an overview. 2015 , 13, 195	167
1686	Breast Surgery in 2015: Advances in Recent Years. 2015 , 22, 3157-60	3
1685	Are we ready to change clinical practice after the 'soft and text' results?. 2015 , 11, 2857-60	1

1684	St. Gallen endocrine response classes predict recurrence rates over time. 2015 , 24, 705-12	5
1683	Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges. 2015 , 418 Pt 3, 322-33	6
1682	Uterine Cancer. 2015 ,	2
1681	Molecular Pathology of Hormone Regulation in Breast Cancer: Hormone Receptor Evaluation and Therapeutic Implications. 2015 , 107-118	
1680	Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. 2015 , 24 Suppl 2, S6-S10	11
1679	Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. 2015 , 153, 539-47	35
1678	Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer. 2015 , 14, 2887-900	18
1677	Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. 2015 , 6, 10044	81
1676	Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. 2015 , 24 Suppl 2, S120-5	15
1675	The Value of Patient and Public Involvement in Trial Design and Development. 2015 , 27, 747-9	8
1674	Utilization and Outcomes of Breast Brachytherapy in Younger Women. 2015 , 93, 91-101	10
1673	Mastectomie bilateral en cancer de mama unilateral. 2015 , 28, 145-147	
1672	Metastasis to the Cervix Uteri 15 Years After Treatment of Lobular Carcinoma of the Breast. 2015 , 42, e81-94	5
1671	Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. 2015 , 15, 570	13
1670	The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer. 2015 , 16, 31	
1669	Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. 2015 , 33, 65-73	103
1668	Selective estrogen receptor modulators (SERMs): a review of clinical data. 2015 , 80, 52-7	60
1667	Breast Diseases. 2015 ,	2

1666	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER-positive advanced breast cancer. 2015 , 15, 235-40	1
1665	The impact of tumor stroma on drug response in breast cancer. 2015 , 31, 3-15	68
1664	Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. 2015 , 34, 506-15	93
1663	Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis. 2015 , 22, 1102-10	19
1662	Prophylactic mastectomy: who needs it, when and why. 2015 , 111, 91-5	15
1661	Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer. 2016 , 23, 128-133	17
1660	Imaging Surveillance of Women With a Personal History of Breast Cancer. 2016 , 299-322	1
1659	MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. 2016 , 7, 61166-61182	15
1658	Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital. 2016 , 8, 47-52	2
1657	Breast Cancer Screening in the Older Woman. 2016 , 189-217	
1656	Radiothérapie du sein et des aires ganglionnaires. 2016 , 137-141	
1655	Integrating Personalization of Treatment with Tamoxifen into Pharmacy Practice Via Clinical Pharmacist Role in Therapy Management. 2016 , 3,	
1654	Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells. 2016 , 8, 211-221	4
1653	Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis. 2016 , 22, 969-78	15
1652	Hormonothérapie adjuvante dans le cancer du sein. 2016 , 95-107	
1651	Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. 2016 , 10, 609	25
1650	Recent advances in the medical treatment of breast cancer. 2016 , 5, 2786	8
1649	Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. 2016 , 34, 4398-4404	20

1648	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. 2016 , 35, e40-54	25
1647	Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. 2016 , 7, 57239-57253	24
1646	Specific Aspects of Breast Cancer Therapy of Elderly Women. 2016 , 2016, 1381695	20
1645	Construction of a Nanodiamond-Tamoxifen Complex as a Breast Cancer Drug Delivery Vehicle. 2016 , 2016, 1-9	7
1644	Function of G-Protein-Coupled Estrogen Receptor-1 in Reproductive System Tumors. 2016 , 2016, 7128702	19
1643	Contralateral prophylactic mastectomy: current perspectives. 2016 , 8, 213-23	32
1642	[Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence]. 2016 , 144, 1326-1335	4
1641	Tamoxifen Resistance: Emerging Molecular Targets. 2016 , 17,	67
1640	Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells. 2016 , 7, 2408-2419	31
1639	The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. 2016 , 5,	68
1638	Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status. 2016 , 6, 100	4
1637	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. 2016 , 11, e0163254	5
1636	Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. 2016 , 11, e0148849	2
1635	Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods. 2016 , 11, e0157322	4
1634	Origin of aromatase inhibitory activity via proteochemometric modeling. 2016 , 4, e1979	13
1633	Bayesian adjustment for the misclassification in both dependent and independent variables with application to a breast cancer study. 2016 , 35, 4252-63	1
1632	Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis. 2016 , 35, 3704-16	7
1631	Highlights of the San Antonio Breast Cancer Symposium 2015: part 1. 2016 , 12, 893-6	2

1630	A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. 2016 , 138, 2088-97	60
1629	Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. 2016 , 56, 1570-1581	15
1628	How Beneficial is Follow-Up Mammography in Elderly Breast Cancer Survivors?. 2016 , 23, 3518-3523	6
1627	Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women. 2016 , 76, 516-524	3
1626	Breast Cancer Survivorship. 2016 ,	3
1625	Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. 2016 , 16, 430	12
1624	Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. 2016 , 6, 38037	13
1623	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. 2016 , 76, 7012-7023	41
1622	Inhibition of the MAPK pathway alone is insufficient to account for all of the cytotoxic effects of naringenin in MCF-7 breast cancer cells. 2016 , 3, 64-71	14
1621	Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies. 2016 , 144, 487-537	19
1620	The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer. 2016 , 17, 1861-1864	
1619	Waiting time for radiation therapy after breast-conserving surgery in early breast cancer: a retrospective analysis of local relapse and distant metastases in 615 patients. 2016 , 21, 32	7
1618	The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. 2016 , 164, 236-43	29
1617	Decision-Making Regarding Mammography Screening for Older Women. 2016 , 64, 2413-2418	13
1616	The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics. 2016 , 91, 217-223	2
1615	ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. 2016 , 48, 688-98	5
1614	Genetics: Implications for Prevention and Management of Coronary Artery Disease. 2016 , 68, 2797-2818	65
1613	Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer. 2016 , 6, 26304	6

1612 Pharmacogenomics of Breast Cancer. **2016**, 379-401

1611 Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. **2016**, 25, 472-486 141

1610 Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders. **2016**, 37, 659-73 39

1609 Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness. **2016**, 19, 936-944

1608 Exclusive intraoperative radiotherapy for invasive breast cancer in elderly patients (>70 years): proportion of eligible patients and local recurrence-free survival. **2016**, 16, 74 4

1607 Hormone receptor status does not alter the effect of trastuzumab in breast cancer. **2016**, 23, 349-55 5

1606 Adjuvant treatment for older women with invasive breast cancer. **2016**, 12, 129-45; quiz 145-6 9

1605 MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells. **2016**, 35, 2398-404 5

1604 Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications. **2016**, 34, 2093-7 14

1603 AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models. **2016**, 76, 3307-18 126

1602 Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. **2016**, 21, 795-803 28

1601 Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. **2016**, 10, 1078-85 36

1600 Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy. **2016**, 157, 385-394 23

1599 Poor persistence with hormonal therapy among women with breast cancer. **2016**, 7, 154-7

1598 Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. **2016**, 34, 2452-9 127

1597 Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. **2016**, 34, 2350-8 56

1596 Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. **2016**, 35, 4914-26 41

1595 Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study. **2016**, 55, 734-41 4

1594	Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?. 2016 , 107, 398-406	24
1593	Treatment Modification in Young Breast Cancer Patients. 2016 , 39, 122-8	1
1592	Analysis of the Adjuvant Hormone Therapy Randomized Trial. 2016 , 34, 2070	0
1591	Molecular imaging in ovarian cancer. 2016 , 27 Suppl 1, i23-i29	2
1590	Re-Evaluating Clonal Dominance in Cancer Evolution. 2016 , 2, 263-276	33
1589	Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. 2016 , 8, 60-72	1
1588	Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility. 2016 , 22, 3121-3	9
1587	Are SOFT and TEXT results practice changing and how?. 2016 , 27, 122-5	10
1586	Opening the Debate on the New Sepsis Definition. Precision Medicine: An Opportunity to Improve Outcomes of Patients with Sepsis. 2016 , 194, 137-9	11
1585	Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial. 2016 , 34, 2232-8	22
1584	[Normofractionated breast irradiation in breast cancer. Indications and benefits]. 2016 , 20, 564-6	
1583	In vitro cellular radiosensitivity in relationship to late normal tissue reactions in breast cancer patients: a multi-endpoint case-control study. 2016 , 92, 823-836	16
1582	Pushing estrogen receptor around in breast cancer. 2016 , 23, T227-T241	26
1581	Breast Cancer. 2016 , 1313-1328.e15	1
1580	Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. 2016 , 160, 313-322	18
1579	Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. 2016 , 23, 635-50	5
1578	[Not Available]. 2016 , 103, S105-9	
1577	To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review. 2016 , 50, 155-167	15

1576	Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit. 2016 , 5, 159-162	3
1575	Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. 2016 , 11, 425-432	1
1574	Renewed interest in the progesterone receptor in breast cancer. 2016 , 115, 909-911	20
1573	Association of lifestyle and demographic factors with estrogenic and glucocorticogenic activity in Mexican American women. 2016 , 37, 904-911	6
1572	Cancer treatment and survivorship statistics, 2016. 2016 , 66, 271-89	3256
1571	Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. 2016 , 159, 293-303	14
1570	A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. 2016 , 159, 97-108	10
1569	Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. 2016 , 27, 161-163	
1568	Validated biomarkers: The key to precision treatment in patients with breast cancer. 2016 , 29, 192-201	34
1567	Biomarker assessment and molecular testing for prognostication in breast cancer. 2016 , 68, 70-85	44
1566	Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks. 2016 , 23, 3100-5	91
1565	Modified Nucleic Acids in Biology and Medicine. 2016 ,	2
1564	Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. 2016 , 139, 2127-34	22
1563	Hypofractionation with no boost after breast conservation in early-stage breast cancer patients. 2016 , 33, 108	8
1562	Differences between Breast Conservation-Eligible Patients and Unilateral Mastectomy Patients in Choosing Contralateral Prophylactic Mastectomies. 2016 , 22, 607-615	9
1561	Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. 2016 , 14, 223	29
1560	A new three-dimensional conformal radiotherapy (3DCRT) technique for large breast and/or high body mass index patients: evaluation of a novel fields assessment aimed to reduce extra-target-tissue irradiation. 2016 , 89, 20160039	4
1559	From technological advances to biological understanding: The main steps toward high-precision RT in breast cancer. 2016 , 29, 213-22	16

1558	Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. 2016 , 16, 395-403	32
1557	Endocrine treatment in breast cancer: Cure, resistance and beyond. 2016 , 50, 68-81	86
1556	Hyperthermia in Locally Recurrent Breast Cancer. 2016 , 145-158	4
1555	Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. 2016 , 27, 2160-2167	21
1554	Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer. 2016 , 46, 1153-1159	5
1553	Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. 2016 , 159, 71-8	7
1552	The pathway to clinical use of a cancer biomarker. 2016 , 245, S17-21	3
1551	Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. 2016 , 1, e000038	42
1550	Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. 2016 , 7, e2454	68
1549	Recent perspectives of breast cancer prognosis and predictive factors. 2016 , 12, 3674-3678	12
1548	Progress in the clinical detection of heterogeneity in breast cancer. 2016 , 5, 3475-3488	39
1547	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. 2016 , 23, 4253-4261	31
1546	One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity. 2016 , 17, 823-6	15
1545	Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence. 2016 , 68, 176-178	2
1544	Breast Cancer in the Bahamas in 2009-2011. 2016 , 10, 45-52	7
1543	Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. 2016 , 354, i5014	26
1542	Revisiting the drug interaction between tamoxifen and SSRI antidepressants. 2016 , 354, i5309	16
1541	Tamoxifen Action in ER-Negative Breast Cancer. 2016 , 5, 1-7	47

1540	Adjuvante endokrine Therapie des Mammakarzinoms. 2016 , 19, 40-47	1
1539	Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. 2016 , 18, 65	26
1538	Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). 2016 , 18, 93	6
1537	Association between depressive disorders and risk of breast cancer recurrence after curative surgery. 2016 , 95, e4547	7
1536	Approaches for predicting effects of unintended environmental exposure to an endocrine active pharmaceutical, tamoxifen. 2016 , 31, 1834-1850	5
1535	Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. 2016 , 157, 475-88	29
1534	Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients. 2016 , 294, 377-84	7
1533	News on the medical treatment of young women with early-stage HER2-negative breast cancer. 2016 , 17, 1643-55	7
1532	Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. 2016 , 158, 195-202	26
1531	Tumor-associated macrophage-derived CXCL8 could induce ER β suppression via HOXB13 in endometrial cancer. 2016 , 376, 127-36	34
1530	The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors. 2016 , 12, 851-63	2
1529	Die gegenwärtige Landschaft der endokrinen Therapie für prämenopausale Frauen mit Brustkrebs. 2016 , 3, 14-18	
1528	Going off the grid: ER β breast cancer beyond estradiol. 2016 , 57, F1-5	2
1527	Les traitements adjuvants des cancers du sein : dernières avancées et perspectives pour des cancers très différents. 2016 , 18, 120-127	1
1526	¹⁸ F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications. 2016 , 57, 1269-75	56
1525	Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis. 2016 , 2, 412-421	51
1524	The Role of mTOR Inhibitors in Breast Cancer. 2016 , 67-92	
1523	Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. 2016 , 155, 303-11	2

1522	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. 2016 , 34, 927-35	252
1521	[New options in adjuvant endocrine therapy in breast cancer]. 2016 , 103, 104-12	2
1520	Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. 2016 , 16, 211-8	11
1519	Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype. 2016 , 155, 85-97	14
1518	Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. 2016 , 55, 249-55	16
1517	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. 2016 , 45, 87-96	150
1516	Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. 2016 , 882, 125-54	27
1515	Obesity and Cancer Opportunities to Break the Link. 2016 , 8, 22-31	4
1514	Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype. 2016 , 25, 326-36	31
1513	Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments. 2016 , 15, 911-23	7
1512	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. 2016 , 34, 2303-11	61
1511	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. 2016 , 155, 483-90	24
1510	Adjuvant treatment for breast cancer. 2016 , 34, 43-46	1
1509	Patterns in target-directed breast cancer research. 2016 , 5, 109	
1508	Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D. 2016 , 33, 19	17
1507	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. 2016 , 16, 541-51	3
1506	Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. 2016 , 26, 106-14	49
1505	Sisyphian Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. 2016 , 34, 895-7	

1504	Prognostic role of sex steroid receptors in pancreatic adenocarcinoma. 2016 , 212, 38-43	8
1503	Second international consensus guidelines for breast cancer in young women (BCY2). 2016 , 26, 87-99	84
1502	Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. 2016 , 27, 459-72	46
1501	Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. 2016 , 23, 830-843	26
1500	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. 2016 , 23, 329-42	24
1499	Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer. 2016 , 16, 284-90	1
1498	Immunohistochemistry for Triple-Negative Breast Cancer. 2016 , 1406, 39-51	2
1497	Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. 2016 , 34, 1573-9	13
1496	Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment. 2016 , 55 Suppl 2, 24-35	29
1495	The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition. 2016 , 23, 391-9	2
1494	Sphingosine-1-phosphate and estrogen signaling in breast cancer. 2016 , 60, 160-165	33
1493	Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K. 2016 , 340, 125-31	11
1492	Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?. 2016 , 18, 770-9	12
1491	Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. 2016 , 22, 2250-60	23
1490	Selective estrogen receptor modulators and betulinic acid act synergistically to target ER α and SP1 transcription factor dependent Pygopus expression in breast cancer. 2016 , 69, 518-26	9
1489	New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. 2016 , 42, 18-23	10
1488	Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. 2016 , 37, 5811-9	12
1487	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 2016 , 22, 337-45	43

1486	Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. 2016 , 14, 207-15	16
1485	Setup error and motion during deep inspiration breath-hold breast radiotherapy measured with continuous portal imaging. 2016 , 55, 193-200	23
1484	Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation. 2016 , 5, e1074375	13
1483	Surgical management of pituitary metastases. 2016 , 19, 11-8	11
1482	Trial watch - inhibiting PARP enzymes for anticancer therapy. 2016 , 3, e1053594	18
1481	Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years. 2016 , 115, 249-56	2
1480	Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types. 2016 , 23, 415-24	6
1479	Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. 2017 , 23, 407-415	62
1478	Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. 2017 , 387, 25-31	15
1477	Mapping the Decision-Making Process for Adjuvant Endocrine Therapy for Breast Cancer: The Role of Decisional Resolve. 2017 , 37, 79-90	19
1476	Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. 2017 , 26, e12339	16
1475	Long-term prospective assessment of shoulder function after breast reconstruction involving a latissimus dorsi muscle flap transfer and postoperative radiotherapy. 2017 , 24, 362-368	6
1474	Older Patients With Early-stage Breast Cancer: Adjuvant Radiation Therapy and Predictive Factors for Cancer-related Death. 2017 , 40, 300-305	9
1473	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. 2017 , 32, 79-86	10
1472	Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. 2017 , 54, 24-33	60
1471	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER+metastatic breast cancer. 2017 , 49, 444-450	46
1470	[Systemic neoadjuvant therapy of luminal breast cancer in 2016]. 2017 , 104, 69-78	2
1469	Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX Breast Recurrence Score Assay. 2017 , 43, 921-930	18

1468	Extended adjuvant endocrine therapy - A standard to all or some?. 2017 , 32, 112-118	7
1467	Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. 2017 , 3, 928-935	24
1466	First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. 2017 , 17, 3	20
1465	Imaging Surveillance After Primary Breast Cancer Treatment. 2017 , 208, 676-686	36
1464	Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. 2017 , 56, 614-617	12
1463	Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. 2017 , 55, 26-35	15
1462	BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo. 2017 , 17, 115	5
1461	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. 2017 , 18, 4	13
1460	Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?. 2017 , 28, 215-225	6
1459	Vitamin D receptor as a target for breast cancer therapy. 2017 , 24, 181-195	31
1458	New Insights in Estrogen Receptor (ER) Biology and Implications for Treatment. 2017 , 9, 13-25	2
1457	Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. 2017 , 1865, 488-498	16
1456	Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. 2017 , 70, 320-326	23
1455	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. 2017 , 17, 297-310	3
1454	Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. 2017 , 163, 321-330	17
1453	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). 2017 , 75, 284-298	265
1452	Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils. 2017 , 5, 234-247	41
1451	Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors. 2017 , 26, 930-937	26

1450	Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. 2017 , 17, 319-326	5
1449	Developing and validating a theoretical measure of modifiable influences on hormonal therapy medication taking behaviour in women with breast cancer. 2017 , 32, 1308-1326	2
1448	Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review. 2017 , 23, 694-705	9
1447	Extended Endocrine Therapy: Is 5 Years Enough?. 2017 , 19, 16	3
1446	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo. 2017 , 89, 827-837	28
1445	Tamoxifen Decreases Mortality, but How?. 2017 , 35, 379	1
1444	Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast. 2017 , 17, 115	14
1443	Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis. 2017 , 163, 1-10	20
1442	Leveraging information from genetic risk scores of coronary atherosclerosis. 2017 , 28, 104-112	11
1441	Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. 2017 , 143, 1701-1712	23
1440	Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. 2017 , 78, 37-44	22
1439	Selective Activation of Estrogen Receptor β Activation Function-1 Is Sufficient to Prevent Obesity, Steatosis, and Insulin Resistance in Mouse. 2017 , 187, 1273-1287	28
1438	A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis. 2017 , 56, 1161-1167	3
1437	The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy. 2017 , 164, 285-294	9
1436	Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women. 2017 , 18, 28	10
1435	Combined Inhibition of Both p110 α and p110 β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER Breast Cancer. 2017 , 23, 2795-2805	23
1434	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. 2017 , 77, 1313-1336	25
1433	Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials. 2017 , 34, 131	9

1432	Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer. 2017 , 9, 100-110	6
1431	Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors. 2017 , 96, e7147	24
1430	Current strategies in the diagnosis of endometrial cancer. 2017 , 296, 5-14	7
1429	Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change. 2017 , 23, 2655-2664	20
1428	New Approaches for Tailoring the Use of Radiotherapy in Early-Stage Breast Cancer. 2017 , 9, 129-136	
1427	Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status. 2017 , 26, 1266-1275	19
1426	Clinical utility of gene-expression signatures in early stage breast cancer. 2017 , 14, 595-610	127
1425	St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. 2017 , 12, 102-107	87
1424	PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. 2017 , 96, 469-475	9
1423	Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach. 2017 , 164, 119-131	11
1422	Which women decide to take tamoxifen?. 2017 , 164, 149-155	5
1421	Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?. 2017 , 123, 2626-2633	11
1420	Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer. 2017 , 1868, 148-156	10
1419	Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: A systematic review and meta-analysis. 2017 , 123, 1-9	31
1418	Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. 2017 , 23, 4493-4500	12
1417	Utility of F-fluoroestradiol (F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy. 2017 , 44, 500-508	19
1416	An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. 2017 , 161, 567-574	17
1415	Stereotactic ablative body radiotherapy (SABR) for oligometastatic cancer. 2017 , 90, 20160500	11

1414	The role of sex hormones and steroid receptors on female reproductive cancers. 2017 , 118, 93-108	80
1413	Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. 2017 , 185, 75-85	27
1412	Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. 2017 , 152, 274-282	84
1411	Significant Effect of Polymorphisms in on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. 2017 , 23, 2019-2026	20
1410	Effects of Electroporation on Tamoxifen Delivery in Estrogen Receptor Positive (ER+) Human Breast Carcinoma Cells. 2017 , 75, 103-109	2
1409	New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. 2017 , 23, 1126-1131	10
1408	Quality indicators in breast cancer care: An update from the EUSOMA working group. 2017 , 86, 59-81	96
1407	Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women. 2017 , 9, 236-241	3
1406	Contralateral Prophylactic Mastectomy. 2017 , 377, 1288-1291	5
1405	Resource-stratified implementation of a community-based breast cancer management programme in Peru. 2017 , 18, e607-e617	21
1404	Imaging Neoadjuvant Therapy Response in Breast Cancer. 2017 , 285, 358-375	88
1403	Estrogen receptor quantitative measures and breast cancer survival. 2017 , 166, 855-864	11
1402	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). 2017 , 35, 203-217	163
1401	Trends in adherence to NCCN guidelines for breast conserving therapy in women with Stage I and II breast cancer: Analysis of the 1998-2008 National Cancer Data Base. 2017 , 26, 359-367	5
1400	Preservaci3n de la fertilidad femenina. 2017 , 53, 1-15	1
1399	An Update on Randomized Clinical Trials in Breast Cancer. 2017 , 26, 587-620	6
1398	Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study. 2017 , 44, E101-E110	22
1397	A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR Early-Stage Breast Cancer with One to Three Positive Nodes. 2017 , 23, 7217-7224	18

- 1396 The Role of Sex Steroids in Angiogenesis. **2017**, 445-471
- 1395 Whole-Breast Hypofractionated Radiotherapy. **2017**, 127-139
- 1394 Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. **2017**, 60, 53-59 17
- 1393 FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ER-Positive Breast Cancer Cells. **2017**, 19, 791-804 23
- 1392 Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the and genes. **2017**, 3, 30 10
- 1391 A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III -Mutant ER-Positive and HER2-Negative Breast Cancer. **2017**, 23, 6823-6832 51
- 1390 CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. **2017**, 166, 277-287 15
- 1389 Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. **2017**, 285, 401-413 59
- 1388 The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. **2017**, 187, 2185-2198 9
- 1387 Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe!. **2017**, 36, 86-88 2
- 1386 Development of a silicon diode detector for skin dosimetry in radiotherapy. **2017**, 44, 5402-5412 4
- 1385 Loss of p27 increases genomic instability and induces radio-resistance in luminal breast cancer cells. **2017**, 7, 595 16
- 1384 Body mass index, waist-to-hip ratio and late outcomes: a report from the Shanghai Breast Cancer Survival Study. **2017**, 7, 6996 11
- 1383 Luteinizing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. **2017**, 18, 1357-1362 4
- 1382 Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors. **2017**, 8, 408-412 1
- 1381 Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer. **2017**, 12, 138-144 2
- 1380 Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer. **2017**, 14, 2334-2340 5
- 1379 Conditional disease-free survival among patients with breast cancer. **2017**, 96, e5746 7

1378	Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. 2017 , 166, 593-601	11
1377	Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. 2017 , 13, 2733-2736	1
1376	Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?. 2017 , 39, 1010428317731511	11
1375	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 2017 , 377, 1836-1846	610
1374	Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-Hydroxylase expression. 2017 , 108, 2454-2461	10
1373	Endocrine Therapies in the Adjuvant and Advanced Disease Settings. 2017 , 557-568	
1372	Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. 2017 , 165, 659-668	5
1371	Cardiac dose-sparing effects of deep-inspiration breath-hold in left breast irradiation : Is IMRT more beneficial than VMAT?. 2017 , 193, 800-811	22
1370	Long-term effect of oncoplastic breast-conserving surgery using latissimus dorsi miniflaps on mammographic surveillance and the detection of local recurrence. 2017 , 70, 1203-1209	16
1369	Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development. 2017 , 134, 453-463	10
1368	Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction. 2017 , 70, 1495-1504	15
1367	Adjuvante endokrine Therapie des Mammakarzinoms. 2017 , 22, 34-40	
1366	Adjuvant endocrine therapy for premenopausal women: Type and duration. 2017 , 34 Suppl 1, S108-S111	5
1365	SPIN90 Depletion and Microtubule Acetylation Mediate Stromal Fibroblast Activation in Breast Cancer Progression. 2017 , 77, 4710-4722	15
1364	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. 2017 , 22, 1292-1300	56
1363	C-Reactive protein: a major inflammatory biomarker. 2017 , 9, 3400-3413	7
1362	Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer. 2017 , 147, 153-157	8
1361	Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. <i>Lancet, The</i> , 2017 , 389, 861-870	40 111

1360	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. 2017 , 109,	178
1359	Breast cancer. <i>Lancet, The</i> , 2017 , 389, 1134-1150	40 923
1358	Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. 2017 , 161, 185-190	13
1357	Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. 2017 , 17, 41-47	17
1356	Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries. 2017 , 24, 400-410	7
1355	Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients. 2017 , 24, 393-399	5
1354	Why Are There So Many Mastectomies in the United States?. 2017 , 68, 229-241	26
1353	Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. 2017 , 3, 186-193	17
1352	Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?. 2017 , 83-84, 50-58	12
1351	Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. 2017 , 25, 75-83	26
1350	Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. 2017 , 161, 279-287	178
1349	Impact of tamoxifen therapy on fertility in breast cancer survivors. 2017 , 107, 243-252.e5	39
1348	[Multimodal imaging of breast cancer recurrence : Prospective intraindividual comparison of F-FDG PET/CT, contrast-enhanced CT, and bone scintigraphy]. 2017 , 57, 1-3	1
1347	Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. 2017 , 31, 173-180	3
1346	The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity. 2017 , 36, 795-801	2
1345	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. 2017 , 70, 456-465	9
1344	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. 2017 , 9, 679-692	10
1343	Studies on DNA Damage Repair and Precision Radiotherapy for Breast Cancer. 2017 , 1026, 105-123	4

1342	Estrogen Receptor α as a Therapeutic Target in Breast Cancer Stem Cells. 2017 , 109, 1-14	48
1341	Cancer Biomarkers: Important Tools for Cancer Diagnosis and Prognosis. 2017 , 1-29	0
1340	Endokrine antihormonelle Therapie in der Prämenopause. 2017 , 27, 147-152	
1339	ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. 2017 , 10, 4859-4867	8
1338	The effect of polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. 2017 , 10, 5429-5437	15
1337	Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients. 2017 , 20, 160-169	9
1336	Urban-Rural Variations in Quality-of-Life in Breast Cancer Survivors Prescribed Endocrine Therapy. 2017 , 14,	10
1335	Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. 2017 , 18,	27
1334	Tumor Heterogeneity in Breast Cancer. 2017 , 4, 227	211
1333	Pitaya Extracts Induce Growth Inhibition and Proapoptotic Effects on Human Cell Lines of Breast Cancer via Downregulation of Estrogen Receptor Gene Expression. 2017 , 2017, 7865073	6
1332	Association of H2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer. 2017 , 7, 945-951	10
1331	Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. 2017 , 35, 1641-1649	348
1330	Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases. 2017 , 93, 657-676	4
1329	Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients. 2017 , 17, 578	4
1328	The association between smoking and breast cancer characteristics and outcome. 2017 , 17, 624	13
1327	Targeting protein quality control pathways in breast cancer. 2017 , 15, 109	19
1326	Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. 2017 , 19, 83	20
1325	Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. 2017 , 17, 632	14

1324	Breast cancer electron intraoperative radiotherapy: assessment of preoperative selection factors from a retrospective analysis of 758 patients and review of literature. 2017 , 165, 261-271	6
1323	African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. 2017 , 166, 743-755	7
1322	Endokrine antihormonelle Therapie in der Prämenopause. 2017 , 20, 151-156	
1321	Utility of Regular Radiological Follow-up on Early Detection of Contralateral Malignancy and Long-term Outcomes in Metachronous Bilateral Breast Cancer Patients. 2017 , 32, 72	
1320	Endocrine Therapy in Older Women with Early-Stage Hormone Sensitive Breast Cancer. 2017 , 06,	
1319	Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients. 2017 , 21, 295-298	1
1318	Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. 2017 , 8, 52156-52177	27
1317	Treatment of Depression in Patients under Breast Cancer Therapy: Antidepressant-Tamoxifen Drug Interactions. 2017 , 08,	
1316	Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer. 2017 , 13, e451-e462	24
1315	Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. 2017 , 35, 86-95	55
1314	Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. 2017 , 37, 106-115	5
1313	Prognostic and predictive value of low estrogen receptor expression in breast cancer. 2017 , 24, e106-e114	17
1312	Chemoprevention Trials. 2017 ,	1
1311	c-Jun/AP-1 overexpression reprograms ER β signaling related to tamoxifen response in ER β positive breast cancer. 2018 , 37, 2586-2600	22
1310	Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review. 2018 , 2, 359-369	4
1309	Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register. 2018 , 57, 935-940	12
1308	[Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies]. 2018 , 47, 594-603	2
1307	Validation of the AJCC 8th prognostic system for breast cancer in an Asian healthcare setting. 2018 , 40, 38-44	19

1306	Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. 2018 , 9, 1595	51
1305	Analytical and clinical performance of progesterone receptor antibodies in breast cancer. 2018 , 35, 21-26	2
1304	Spatial orientation of coronary arteries and its implication for breast and thoracic radiotherapy-proposing "coronary strip" as a new organ at risk. 2018 , 194, 711-718	7
1303	Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. 2018 , 39, 117-122	2
1302	De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients. 2018 , 35, 62	17
1301	Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. 2018 , 73, 545-558	12
1300	Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer. 2018 , 28, 3176-3184	8
1299	Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. 2018 , 110, 726-733	27
1298	Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. 2018 , 154, 670-675	39
1297	Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. 2018 , 10, 1758835918766189	3
1296	OMIP-045: Characterizing human head and neck tumors and cancer cell lines with mass cytometry. 2018 , 93, 406-410	14
1295	Differences between palpable and nonpalpable tumors in early-stage, hormone receptor-positive breast cancer. 2018 , 216, 326-330	4
1294	Tamoxifen enhances stemness and promotes metastasis of ER ⁺ breast cancer by upregulating ALDH1A1 in cancer cells. 2018 , 28, 336-358	68
1293	Endocrine therapy for cancer. 2018 , 36, 128-133	0
1292	Associations between Diet Quality Scores and Risk of Postmenopausal Estrogen Receptor-Negative Breast Cancer: A Systematic Review. 2018 , 148, 100-108	20
1291	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. 2018 , 103, 770-777	161
1290	Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors. 2018 , 48, 248-254	0
1289	Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. 2018 , 24, 1987-2001	19

1288	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. 2018 , 765-785	
1287	The role of the AR/ER ratio in ER-positive breast cancer patients. 2018 , 25, 163-172	23
1286	Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. 2018 , 215, 895-910	49
1285	Fertility preservation in BRCA-mutated women: when and how?. 2018 , 14, 483-490	16
1284	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. 2018 , 105, e158-e168	18
1283	Is invasion a necessary step for metastases in breast cancer?. 2018 , 169, 9-23	34
1282	Exogenous reproductive hormone use in breast cancer survivors and previvors. 2018 , 15, 249-261	15
1281	Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. 2018 , 169, 153-162	5
1280	Anti-estrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ER α Mammary Carcinomas. 2018 , 78, 1672-1684	13
1279	Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. 2018 , 168, 299-310	42
1278	Initiation of Adjuvant Endocrine Therapy in Black and White Women With Breast Cancer. 2018 , 18, 337-346.e1	7
1277	Breast Biomarker Immunocytochemistry. 2018 , 197-206.e6	
1276	Steroid Receptors in Breast Cancer. 2018 , 272-281.e2	2
1275	Therapeutic Strategies for Breast Cancer. 2018 , 315-330.e7	3
1274	Adjuvant Endocrine Therapy. 2018 , 736-751.e4	1
1273	Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. 2018 , 752-762.e4	
1272	Endocrine Therapy for Breast Cancer. 2018 , 907-923.e6	2
1271	Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. 2018 , 186, 1-24	159

1270 Adjuvant Endocrine Therapy. **2018**, 427-438

1269 Breast Cancer in Older Patients. **2018**, 529-540

1268 The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial. **2018**, 57, 113-119 20

1267 Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. **2018**, 16, 51 13

1266 Patterns of Care of Breast Cancer Patients in a Rural Cancer Center in Western India. **2018**, 9, 374-380 3

1265 The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer. **2018**, 183, 1-9 18

1264 Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. **2018**, 19, 26 32

1263 Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe. **2018**, 44, 951-956 7

1262 Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. **2018**, 3, e000301 15

1261 Acquired resistance to aromatase inhibitors: where we stand!. **2018**, 25, R283-R301 45

1260 A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010. **2018**, 38, 89S-98S 7

1259 A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients. **2018**, 170, 271-277 6

1258 Therapeutic potential of melatonin for breast cancer radiation therapy patients. **2018**, 94, 472-477 19

1257 Reply to Katsu and Baker: Using zebrafish PDX to screen drug sensitivity of endocrine-dependent cancers. **2018**, 115, E2910 0

1256 Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. **2018**, 30, 533-538 16

1255 Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis. **2018**, 25, 8-16 6

1254 Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study. **2018**, 14, 198-203 6

1253 Nonsteroidal estrogen receptor isoform-selective biphenyls. **2018**, 91, 620-630 4

1252	Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. 2018 , 103, 243-252	6
1251	The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer. 2018 , 27, 466-475	5
1250	Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. 2018 , 14, e161-e166	7
1249	Prognostic and predictive biomarkers in breast cancer: Past, present and future. 2018 , 52, 56-73	182
1248	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. 2018 , 167, 59-71	23
1247	Estrogen and progesterone signalling in the normal breast and its implications for cancer development. 2018 , 466, 2-14	56
1246	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. 2018 , 110,	76
1245	Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?. 2018 , 24, 881-884	16
1244	The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma. 2018 , 466, 31-37	7
1243	Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. 2018 , 466, 15-30	65
1242	Contralateral Prophylactic Mastectomy: Current Perspectives. 2018 , 33-46	1
1241	Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. 2018 , 57, 26-30	2
1240	Molecular Diagnosis and Targeting Therapy for Breast Cancer. 2018 , 33-47	
1239	The Role of Breast Cancer Chemoprevention in High-Risk Women. 2018 , 79-87	
1238	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. 2018 , 25, R83-R113	11
1237	Volumetric modulated arc therapy (VMAT) to deliver nodal irradiation in breast cancer patients. 2017 , 35, 1	11
1236	Oncotype DX in breast cancer patients: clinical experience, outcome and follow-up-a case-control study. 2018 , 297, 443-447	5
1235	Disseminated breast tumour cells: biological and clinical meaning. 2018 , 15, 129-131	24

1234	Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. 2018 , 57, 3-12	10
1233	Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. 2018 , 124, 482-490	10
1232	Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. 2018 , 32, 1222-1235	16
1231	Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. 2018 , 17, 306-315	37
1230	Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study. 2018 , 37, 107-113	6
1229	Lobular Breast Cancer: Different Disease, Different Algorithms?. 2018 , 27, 81-94	20
1228	Neoadjuvant Endocrine Therapy: Who Benefits Most?. 2018 , 27, 121-140	2
1227	Molecular Subtypes and Local-Regional Control of Breast Cancer. 2018 , 27, 95-120	180
1226	MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells. 2018 , 14, 812-824	49
1225	The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients. 2018 , 41, 708-715	23
1224	Virtual Double Staining: A Digital Approach to Immunohistochemical Quantification of Estrogen Receptor Protein in Breast Carcinoma Specimens. 2018 , 26, 620-626	14
1223	Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial. 2018 , 59, 197-203	21
1222	Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. 2018 , 9, 8810-8822	11
1221	Do Genomic Assays Provide the Necessary Confidence to De-escalate Adjuvant Therapy?. 2018 , 36, 725-727	1
1220	The Role of Quality Measures in Improving Breast Cancer Care in Low-Income Countries. 2018 , 10, 196-201	1
1219	Aktuelle Therapiestrategien beim primären Mammakarzinom. 2018 , 23, 38-46	
1218	Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. 2018 , 36, 2630-2638	26
1217	Advances in Fertility Preservation for Young Women With Cancer. 2018 , 38, 27-37	8

1216	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. 2018 , 38, 78-86	20
1215	Aktuelle Therapiestrategien beim primären Mammakarzinom. 2018 , 21, 21-29	
1214	Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. 2018 , 7, 449-457	6
1213	Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data. 2018 , 18, 1214	12
1212	MicroRNA-663b mediates TAM resistance in breast cancer by modulating TP73 expression. 2018 , 18, 1120-1126	8
1211	Radiation induced secondary malignancies: a review article. 2018 , 36, 85-94	96
1210	Prognostic Biomarkers for Breast Cancer Metastasis. 2018 ,	
1209	Adjuvante endokrine Therapie beim frühen Mammakarzinom. 2018 , 51, 972-979	
1208	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. 2018 ,	1
1207	Moving Precision Oncology Forward Amid Myths and Misconceptions. 2018 , 4, 1789-1790	2
1206	Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer. 2018 , 12, 821	5
1205	CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. 2018 , 20, 149	7
1204	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. 2018 , 78, 1056-1088	44
1203	12 Medical Treatment of Breast Cancer. 2018 ,	
1202	The Role of Notch in Breast Cancer. 2018 , 227-240	
1201	Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. 2018 , 78, 1110-1118	5
1200	Inverse association between estrogen receptor- β DNA methylation and breast composition in adolescent Chilean girls. 2018 , 10, 122	3
1199	Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. 2018 , 363, k3845	53

1198	S3-Leitlinie: Endokrine Therapie des primären Mammakarzinoms. 2018 , 51, 548-555	2
1197	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. 2018 , 18, 932	2
1196	The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials. 2018 , 13, e0204202	1
1195	American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. 2018 , 38, 1921-1933	34
1194	Translational Methods in Nephrology: Individual Treatment Effect Modeling. 2018 , 29, 2615-2618	1
1193	Nonhormonal selective estrogen receptor modulator 1-(2-[4-((3R,4S)-7-Methoxy-2,2-dimethyl-3-phenyl-chroman-4yl}phenoxy)ethyl)pyrrolidine hydrochloride (ormeloxifene hydrochloride) for the treatment of breast cancer. 2018 , 79, 275-286	4
1192	Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site. 2018 , 38, 6023-6026	7
1191	Stem Cell Applications for Treatment of Cancer and Autoimmune Diseases: Its Promises, Obstacles, and Future Perspectives. 2018 , 17, 1533033818806910	12
1190	Different radiation techniques to deliver therapeutic dose to the axilla in patients with sentinel lymph node-positive breast cancer: Doses, techniques challenges and clinical considerations. 2018 , 22, 767-772	2
1189	The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients. 2018 , 10,	4
1188	Is Monitoring Mean Platelet Volume Necessary in Breast Cancer Patients?. 2018 , 13, 450-455	1
1187	Phased Implementation as a Strategy for Stepwise, Sustainable Improvement in Breast Healthcare in Low-Resource Settings. 2018 , 10, 307-312	
1186	Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. 2018 , 119, 922-927	2
1185	Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. 2018 , 18, 977	8
1184	SIRT1 and Estrogen Signaling Cooperation for Breast Cancer Onset and Progression. 2018 , 9, 552	18
1183	Mammakarzinom: Was bringt die S3-Leitlinienaktualisierung Neues?. 2018 , 51, 807-815	
1182	Genome-Wide Investigation of Genes Regulated by ER in Breast Cancer Cells. 2018 , 23,	5
1181	microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy. 2018 , 20, 17	30

1180	Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review. 2018 , 111, 205-212	3
1179	SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment. 2018 , 7,	11
1178	A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study. 2018 , 13, e0201606	1
1177	Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals. 2018 , 10, 189-199	5
1176	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. 2018 , 70, 138-143	6
1175	Signaling pathways and steroid receptors modulating estrogen receptor function in breast cancer. 2018 , 32, 1141-1154	60
1174	Revisiting the dynamic cancer stem cell model: Importance of tumour edges. 2018 , 131, 35-45	20
1173	Prognosis and Prediction in Breast Cancer: Is There a Need for Further Tests?. 2018 , 3, 159-162	
1172	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. 2018 , 24, 4887-4899	35
1171	Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?. 2018 , 141, 805e-813e	5
1170	Essential oil from as the potential inhibitor for HSP90. 2018 , 5, 489-496	10
1169	Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?. 2018 , 67, 78-87	22
1168	Notoginsenoside R prevents H9c2 cardiomyocytes apoptosis against hypoxia/reoxygenation the ERs/PI3K/Akt pathway.. 2018 , 8, 13871-13878	4
1167	Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study. 2018 , 25, 639-649	2
1166	Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. 2018 , 25, 663-670	10
1165	Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men. 2018 , 4, e181114	9
1164	Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. 2018 , 83, 65-91	21
1163	Prognostic and clinicopathological value of CXCL12/SDF1 expression in breast cancer: A meta-analysis. 2018 , 484, 72-80	6

1162	Breast cancer and ovarian tissue cryopreservation: Review of the literature. 2018 , 47, 351-357	9
1161	Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. 2018 , 98, 1438-1448	52
1160	Correlation Between Contrast-enhanced Ultrasound Characteristics (Qualitative and Quantitative) and Pathological Prognostic Factors in Breast Cancer. 2018 , 32, 945-954	11
1159	The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer. 2018 , 115, 316-323	18
1158	Tamoxifen and ER β : Fertilizing the seeds of breast cancer metastasis. 2018 , 28, 391-392	2
1157	Overview of Breast Cancer Therapy. 2018 , 13, 339-354	120
1156	Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer. 2018 , 35, 113	5
1155	Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers. 2018 , 13, 445-457	8
1154	High collagen density augments mTOR-dependent cancer stem cells in ER α mammary carcinomas, and increases mTOR-independent lung metastases. 2018 , 433, 1-9	16
1153	Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF- κ B signaling. 2018 , 8, 9575	43
1152	Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer. 2018 , 2018, 4931852	3
1151	Uncovering pseudotemporal trajectories with covariates from single cell and bulk expression data. 2018 , 9, 2442	38
1150	Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?. 2018 , 11, 950-956	11
1149	Carbon Nanomaterials for Breast Cancer Treatment. 2018 , 2018, 1-9	23
1148	FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. 2018 , 12, 1884-1894	11
1147	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. 2018 , 171, 737-745	22
1146	Breast cancer stem cells: Features, key drivers and treatment options. 2018 , 53, 59-74	80
1145	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. 2018 , 119, 408-418	31

1144	Development of a Novel Proteomic Risk-Classifer for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. 2018 , 13, 1177271918789100	11
1143	Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma. 2018 , 4, 17	1
1142	Molecular Regulation of Carcinogenesis: Friend and Foe. 2018 , 165, 277-283	18
1141	Evaluation of target dose inhomogeneity in breast cancer treatment due to tissue elemental differences. 2018 , 13, 92	4
1140	Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. 2018 , 19, 1027-1037	6
1139	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. 2018 , 4, 1700-1706	101
1138	Adjuvant Therapy for Resected Renal Cell Carcinoma-Still Searching. 2018 , 74, 621-622	
1137	Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. 2018 , 18, 761	4
1136	Equal Pro-inflammatory Profiles of CCLs, CXCLs, and Matrix Metalloproteinases in the Extracellular Microenvironment in Human Dense Breast Tissue and Breast Cancer. 2017 , 8, 1994	14
1135	Precision Medicine in Hormone Receptor-Positive Breast Cancer. 2018 , 8, 144	22
1134	The times they are a-changin'. 2018 , 21, 81	0
1133	Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. 2018 , 18, 732	20
1132	Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. 2018 , 10, 1758835918776923	19
1131	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. 2018 , 10, 1758835918777437	6
1130	Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. 2018 , 143, 2499-2504	5
1129	Insights on the transport of tamoxifen by gold nanoparticles for MCF-7 breast cancer cells based on SERS spectroscopy. 2018 , 170, 712-717	14
1128	Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention. 2018 , 194, 806-814	19
1127	Benzothienophenone Derivatives Targeting Mutant Forms of Estrogen Receptor- β Hormone-Resistant Breast Cancers. 2018 , 19,	9

1126	Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. 2018 , 172, 143-150	8
1125	Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. 2018 , 6, e885-e893	34
1124	Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects. 2018 , 25, e168-e175	26
1123	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health. 2018 , 159, 2980-2990	13
1122	Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression. 2018 , 18, 19	9
1121	Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis. 2018 , 483, 209-215	8
1120	Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer. 2018 , 13, 49	18
1119	Recent Trends in Local-Regional Recurrence Rates: Implications for Therapeutic Intervention. 2018 , 10, 83-90	
1118	Improved anticancer properties of stem cells derived exosomes by prolonged release from PCL nanofibrous structure. 2018 , 665, 105-110	7
1117	The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality. 2018 , 18, 480-498	2
1116	Estradiol Affects Epstein-Barr Virus Reactivation-Induced Thyrotropin Receptor Antibody and Immunoglobulin Production in Graves' Disease Patients and Healthy Controls. 2018 , 31, 486-491	7
1115	Endocrine therapy for breast cancer in the primary care setting. 2018 , 25, 285-291	24
1114	CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells. 2018 , 436, 87-95	6
1113	In vitro cytotoxic and antiproliferative effects of usnic acid on hormone-dependent breast and prostate cancer cells. 2018 , 32, e22208	8
1112	Adipocytes Promote Early Steps of Breast Cancer Cell Dissemination Interleukin-8. 2018 , 9, 1767	21
1111	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. 2018 , 70, 118-126	9
1110	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies - Part 2. 2018 , 17, 893-915	5
1109	The Evolving Role of Postmastectomy Radiation Therapy. 2018 , 98, 801-817	1

1108	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. 2018 , 379, 122-137	270
1107	The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. 2018 , 171, 477-488	4
1106	Oxidation of Cymantrene Analogues of Ferrocifen: Electrochemical, Spectroscopic, and Computational Studies of the Parent Complex 1,1'-Diphenyl-2-cymantrenylbutene. 2018 , 37, 1910-1918	6
1105	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). 2018 , 99, 9-19	7
1104	The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. 2018 , 24, 4763-4770	21
1103	Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. 2018 , 35, 107	7
1102	Hormone-Responsive Cancers. 2019 , 717-741.e8	1
1101	An aptasensor for rapid and sensitive detection of estrogen receptor alpha in human breast cancer. 2019 , 116, 227-233	13
1100	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. 2019 , 36, 318-340	2
1099	Challenges in Treating Estrogen Receptor-Positive Breast Cancer. 2019 ,	5
1098	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. 2019 , 21, 90	45
1097	Regulation of Immunity in Breast Cancer. 2019 , 11,	23
1096	Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy. 2019 , 15, 363-370	16
1095	Moonlighting Proteins and Cardiopathy in the Spatial Response of MCF-7 Breast Cancer Cells to Tamoxifen. 2019 , 13, e1900029	1
1094	Thrombotic Risk from Chemotherapy and Other Cancer Therapies. 2019 , 179, 87-101	22
1093	Overcoming Resistance to PARP Inhibition. 2019 , 161-189	
1092	The COOH-Terminal Proline-Rich Region of GRP78 Is a Key Regulator of Its Cell Surface Expression and Viability of Tamoxifen-Resistant Breast Cancer Cells. 2019 , 21, 837-848	14
1091	Thrombosis and Hemostasis in Cancer. 2019 ,	1

1090	Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study. 2019 , 19, e654-e667	2
1089	Radiological Staging for Distant Metastases in Breast Cancer Patients with Confirmed Local and/or Locoregional Recurrence: How Useful are Current Guideline Recommendations?. 2019 , 26, 3455-3461	7
1088	Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. 2019 , 8,	6
1087	Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. 2019 , 105, 296-306	26
1086	The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. 2019 , 12, 81	83
1085	Management Strategies for Locally Recurrent Breast Cancer: Redo-Lumpectomy, Redo-Sentinel Node Biopsy, Redo-Radiation. 2019 , 26, 3018-3024	3
1084	Estradiol promotes the progression of ER+ breast cancer through methylation-mediated RSK4 inactivation. 2019 , 12, 5907-5916	6
1083	Social Web and Health Research. 2019 ,	5
1082	Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells. 2019 , 38, 414	20
1081	Breast Cancer during Pregnancy-Current Paradigms, Paths to Explore. 2019 , 11,	13
1080	Genome-Wide Association Studies. 2019 ,	0
1079	The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy. 2019 , 19, 1046	7
1078	Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer. 2019 , 11, 155	6
1077	Dosimetric comparison of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for left-sided chest wall and lymphatic irradiation. 2019 , 20, 36-44	8
1076	Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. 2019 , 11, e10638	30
1075	Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. 2019 , 20, 69-82	26
1074	Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. 2019 , 30, 1776-1783	49
1073	Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies. 2019 , 58, 1581-1593	2

1072	Increased Extracellular Osteopontin Levels in Normal Human Breast Tissue at High Risk of Developing Cancer and Its Association With Inflammatory Biomarkers. 2019 , 9, 746	7
1071	Baihe Zhimu formula attenuates the efficacy of tamoxifen against breast cancer in mice through modulation of CYP450 enzymes. 2019 , 19, 240	3
1070	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. 2019 , 178, 535-544	17
1069	Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. 2019 , 10, 3840	52
1068	ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era. 2019 , 26, 715-716	1
1067	ER α -targeted endocrine therapy, resistance and the role of GPER. 2019 , 152, 108493	11
1066	Duplicitous Dispositions of Micro-RNAs (miRs) in Breast Cancer. 2019 ,	
1065	lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network. 2019 , 10, 850	31
1064	Elevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIa Breast Cancer. 2019 , 105, 275-284	1
1063	Breast cancer. 2019 , 5, 66	698
1062	Breast Cancer Treatment: A Review. 2019 , 321, 288-300	1202
1061	Antitumor effect of XCT790, an ERK α inverse agonist, on ER α -negative endometrial cancer cells. 2019 , 42, 223-235	4
1060	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. 2019 , 111, 641-643	2
1059	Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy. 2019 , 111, 933-942	18
1058	The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype. 2019 , 111, 709-718	27
1057	Tamoxifen and pregnancy: an absolute contraindication?. 2019 , 175, 17-25	21
1056	Factors influencing the use of extended adjuvant endocrine therapy. 2019 , 175, 181-189	4
1055	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. 2019 , 120, 398-403	13

1054	Recent developments in affinity-based selection of aptamers for binding disease-related protein targets. 2019 , 73, 2637-2653	4
1053	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline. 2019 , 37, 1965-1977	31
1052	Prognostic Factors for Luminal B-like Breast Cancer. 2019 , 39, 396-402	2
1051	Adherence to anti-estrogen therapy in women with hormone receptor-positive breast cancer utilizing bubble packaging: a pilot study. 2019 , 177, 395-399	1
1050	Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer. 2019 , 13, 1778-1794	8
1049	Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review. 2019 , 9, 359	39
1048	The use of contralateral prophylactic mastectomy among elderly patients in the United States. 2019 , 177, 175-183	6
1047	Update Mammakarzinom 2018 (Teil 3) [Genomforschung, individualisierte Medizin und Immuntherapien] mitten in einer neuen Ära: Prävention und Therapie des frühen Mammakarzinoms. 2019 , 16, 23-32	
1046	Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. 2019 , 177, 185-195	11
1045	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. 2019 , 177, 115-125	7
1044	Endocrine therapy in the years following a diagnosis of breast cancer: A proof of concept study using the primary care prescription database linked to cancer registration data. 2019 , 61, 185-189	3
1043	Biomarkers for Breast Cancer Treatment. 2019 , 115-124	
1042	Cancer treatment and survivorship statistics, 2019. 2019 , 69, 363-385	1873
1041	Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR. 2019 , 18, 1607-1618	13
1040	Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. 2019 , 125, 3266-3274	19
1039	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. 2019 , 39, 248-260	7
1038	The Impact of Big Data Research on Practice, Policy, and Cancer Care. 2019 , 39, e167-e175	5
1037	S3-Leitlinie Interdisziplinäre Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms [2019], 34, 139-143	

1036	Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?. 2019 , 20, 44	8
1035	Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. 2019 , 12, 523-536	36
1034	NEMP1 Promotes Tamoxifen Resistance in Breast Cancer Cells. 2019 , 57, 813-826	9
1033	The selective estrogen receptor modulator raloxifene mitigates the effect of all-retinal toxicity in photoreceptor degeneration. 2019 , 294, 9461-9475	4
1032	Developing and testing prognostic bio-scoring systems for canine mammary gland carcinomas. 2019 , 17, 479-488	10
1031	Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. 2019 , 46, 19-24	7
1030	Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology. 2019 , 131, 233-236	1
1029	Cardiotoxicity Associated with Radiation for Breast Cancer. 2019 , 127-144	
1028	Comparison of deep inspiration breath hold and free breathing technique in left breast cancer irradiation: a dosimetric evaluation in 40 patients. 2019 , 8, 89	1
1027	Adjuvant treatment for breast cancer. 2019 , 37, 176-180	
1026	Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. 2019 , 25, 3658-3672	21
1025	Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes. 2019 , 19, 215	5
1024	Niduterpenoids A and B: Two Sesterterpenoids with a Highly Congested Hexacyclic 5/5/5/5/3/5 Ring System from the Fungus <i>Aspergillus nidulans</i> . 2019 , 21, 2290-2293	19
1023	[Update of the German S3 breast cancer guideline : What is new for pathologists?]. 2019 , 40, 185-198	4
1022	Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer. 2019 , 1866, 1004-1018	41
1021	Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies. 2019 , 36, 828-841	5
1020	Breast Disease. 2019 ,	
1019	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. 2019 , 37, 105-114	38

1018	Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. 2019 , 37, 858-861	5
1017	Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. 2019 , 37, 1629-1637	73
1016	Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. 2019 , 27, 1021-1036	52
1015	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. 2019 , 37, 97-104	83
1014	A heart atlas for breast radiation therapy and the influence of delineation education on both intra and interobserver variability. 2019 , 37, 420-430	1
1013	Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen. 2019 , 9, 2521	1
1012	"It is not just any pill"-Women's experiences of endocrine therapy after breast cancer surgery. 2019 , 28, e13009	3
1011	Adherence and quality of life in women with breast cancer being treated with oral hormone therapy. 2019 , 27, 3799-3804	6
1010	Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. 2019 , 175, 203-215	7
1009	Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial. 2019 , 110, 53-61	7
1008	Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis. 2019 , 145, 3207-3217	7
1007	Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. 2019 , 175, 487-497	8
1006	ER/HER2 Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER/HER2 Breast Cancer. 2019 , 19, 236-245	34
1005	Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. 2019 , 175, 287-295	10
1004	Factors predicting medication prescription adherence in Appalachian breast cancer patients. 2019 , 25, 338-339	1
1003	Evaluation of the Patient Profile and Current Pattern of Care with Docetaxel Based Adjuvant Regimen in Operable Breast Cancer. 2019 , 7, 4-10	
1002	Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. 2019 , 25, 7485-7496	7
1001	[Endocrine adjuvant treatment specific features for young breast cancer women]. 2019 , 106, S24-S27	2

1000	Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis. 2019 , 24, e1014-e1023	1
999	F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with F-FDG PET/CT. 2019 , 24, e1277-e1285	13
998	Effect of the anticancer drug tamoxifen on chronic toxoplasmosis in experimentally infected rats. 2019 , 13, 259-265	0
997	Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer. 2020 , 107, 33-43	15
996	Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study). 2019 , 14, 204	14
995	Treatment specific toxicities: Hormones, antihormones, radiation therapy. 2019 , 46, 414-420	5
994	Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. 2019 , 48 Suppl 1, S89-S91	2
993	[LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?]. 2019 , 106, 342-353	1
992	Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. 2019 , 48 Suppl 1, S85-S88	0
991	Breast Cancer Care Quality in South Africa's Public Health System: An Evaluation Using American Society of Clinical Oncology/National Quality Forum Measures. 2019 , 5, 1-16	7
990	Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer. 2019 , 10, 6175-6184	45
989	Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. 2019 , 20, 81	9
988	Patterns of relapse in older women diagnosed with estrogen receptor (ER) positive early-stage breast cancer (BC) treated with lumpectomy without adjuvant endocrine therapy (ET). 2019 , 8, 349-353	
987	In Reply to Braunstein. 2019 , 105, 1162-1163	
986	Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. 2019 , 1-26	
985	Expression of HIF-1 β s related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. 2019 , 14, e0226150	26
984	Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study. 2019 , 42, 588-595	12
983	Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer. 2019 , 79, 1328-1335	0

982	[Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction]. 2019 , 106, 1104-1114	
981	Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer. 2019 , 33, 1644-1657	10
980	Progress in adjuvant systemic therapy for breast cancer. 2019 , 16, 27-44	96
979	Side effects of drugs for osteoporosis and metastatic bone disease. 2019 , 85, 1063-1071	38
978	CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. 2019 , 30, 103-112	7
977	Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. 2019 , 124, 309-314	17
976	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. 2019 , 145, 274-283	3
975	The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. 2019 , 125, 374-381	13
974	CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. 2019 , 173, 521-532	18
973	Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer. 2019 , 299, 533-541	4
972	The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale. 2019 , 151-188	1
971	SEOM clinical guidelines in early stage breast cancer (2018). 2019 , 21, 18-30	22
970	Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors. 2019 , 43, 48-54	10
969	Estrogen Receptor and Breast Cancer. 2019 ,	3
968	Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer. 2019 , 474, 193-200	15
967	Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study. 2019 , 58, 168-174	4
966	The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. 2019 , 19, e370-e375	2
965	MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. 2019 , 43, 31-38	19

964	Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis. 2019 , 83, 71-79	6
963	Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer. 2019 , 42, 1-12	42
962	Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. 2019 , 125, 269-277	13
961	Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?. 2019 , 125, 213-222	18
960	Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer. 2019 , 47, 641-652	3
959	Hormonal Treatment of Breast Cancer. 2019 , 646-655	1
958	Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. 2019 , 71, 1-19	30
957	Depression enhanced the production of autoantibodies against 16 β hydroxyestrone-estrogen receptor adduct in breast cancer. 2019 , 66, 251-259	2
956	The use of selective estrogen receptor modulators on bone health in men. 2019 , 22, 89-101	9
955	Effects of Menopausal Symptoms and Depression on the Quality of Life of Premenopausal Women With Breast Cancer in Korea. 2019 , 30, 8-16	5
954	Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. 2020 , 34, 61-68	6
953	Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors. 2020 , 28, 271-278	10
952	Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis. 2020 , 22, 474-485	8
951	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. 2020 , 38, 434-443	28
950	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. 2020 , 179, 217-227	7
949	Multigene assays in early breast cancer: Insights from recent phase 3 studies. 2020 , 46, 656-666	11
948	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. 2020 , 38, 1258-1267	19
947	Long-term prognostic effect of hormone receptor subtype on breast cancer. 2020 , 179, 139-151	2

946	Tumor Liquid Biopsies. 2020 ,	5
945	Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. 2020 , 179, 275-285	11
944	Cancer of the Breast. 2020 , 1560-1603.e12	6
943	Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence. 2020 , 27, 54-61	13
942	Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient. 2020 , 15, 72-74	3
941	Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases. 2020 , 20, e151-e163	4
940	Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database. 2020 , 247, 211-219	7
939	Hormone Effects on Tumors. 2020 , 667-693	1
938	Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy. 2020 , 22, 1078-1085	4
937	The Effects of Adjuvant Tamoxifen Use on Macula Pigment Epithelium Optical Density, Visual Acuity and Retinal Thickness in Patients with Breast Cancer. 2020 , 45, 623-628	0
936	Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation. 2020 , 126, 487-495	22
935	The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer. 2020 , 13, 284-292	11
934	Factors influencing medication-taking behaviour with adjuvant endocrine therapy in women with breast cancer: A qualitative systematic review. 2020 , 76, 445-458	6
933	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. 2020 , 27, 2229-2237	4
932	Single Hormone Receptor-Positive Breast Cancer-Signal or Noise?. 2020 , 3, e1918176	1
931	Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors. 2020 , 28, 4147-4154	3
930	Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/ β -catenin Pathway. 2020 , 13, 423-440	5
929	Hybrid planning techniques for hypofractionated whole-breast irradiation using flattening filter-free beams. 2020 , 196, 376-385	6

928	Translational Potential of Rats in Research. 2020 , 77-88	3
927	Proactive visual and statistical analysis of genomic data in Epiviz. 2020 , 36, 2195-2201	1
926	Pharmacogenomics and Endocrine Therapy in Breast Cancer. 2020 , 38, 525-528	3
925	Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. 2020 , 3, e1918160	28
924	Histone methyltransferases regulate the transcriptional expression of ER α and the proliferation of tamoxifen-resistant breast cancer cells. 2020 , 180, 45-54	13
923	Association between low doses of ionizing radiation, administered acutely or chronically, and time to onset of stroke in a rat model. 2020 , 61, 666-673	1
922	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. 2020 , 22, 101	5
921	CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcariol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells. 2020 , 83, 3080-3092	6
920	Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. 2020 , 12,	3
919	Nationwide survey of Japanese breast oncology and reproductive endocrinology departments about the impact of breast cancer treatment on fertility. 2020 , 46, 2488	0
918	Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. 2020 , 2020, 5418365	2
917	Development and Validation of a Next-Generation Sequencing-Based Multigene Assay to Predict the Prognosis of Estrogen Receptor-Positive, HER2-Negative Breast Cancer. 2020 , 26, 6513-6522	1
916	Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs. 2020 , 11, 538734	2
915	Landmark trials in the medical oncology management of early stage breast cancer. 2020 , 47, 278-292	0
914	Selective estrogen receptor modulators (SERMS): keys to understanding their function. 2020 , 27, 1171-1176	8
913	Second primary breast cancer after unilateral mastectomy alone or with contralateral prophylactic mastectomy. 2020 , 9, 8043-8052	3
912	Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer. 2020 , 10, 15415	1
911	CD63 Cancer-Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR-22. 2020 , 7, 2002518	27

910	No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA). 2020 , 142, 38-44	9
909	Therapie des fortgeschrittenen hormonrezeptor(HR)-positiven HER2-negativen Mammakarzinoms. 2020 , 17, 23-30	
908	Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016. 2020 , 20, 847	2
907	Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. 2020 , 22, 123	1
906	Estrogens Determine Adherens Junction Organization and E-Cadherin Clustering in Breast Cancer Cells via Amphiregulin. 2020 , 23, 101683	7
905	A Metal-Polymer Hybrid Biomimetic System for use in the Chemodynamic-Enhanced Photothermal Therapy of Cancers. 2020 , 16, e2004161	24
904	Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer. 2020 , 495, 145-155	11
903	Changing Behavior Using Social Cognitive Theory. 2020 , 32-45	3
902	Changing Behavior Using the Model of Action Phases. 2020 , 77-88	88
901	Changing Behavior Using Habit Theory. 2020 , 178-192	2
900	Changing Behavior by Changing Environments. 2020 , 193-207	3
899	Changing Behavior Using Social Identity Processes. 2020 , 225-236	2
898	Changing Behavior Using Ecological Models. 2020 , 237-250	11
897	Design, Implementation, and Evaluation of Behavior Change Interventions: A Ten-Task Guide. 2020 , 269-284	6
896	Moving from Theoretical Principles to Intervention Strategies: Applying the Experimental Medicine Approach. 2020 , 285-299	8
895	Developing Behavior Change Interventions. 2020 , 300-317	3
894	Evaluation of Behavior Change Interventions. 2020 , 318-332	
893	Implementation Science and Translation in Behavior Change. 2020 , 333-348	1

892	Engagement of Stakeholders in the Design, Evaluation, and Implementation of Complex Interventions. 2020 , 349-360	3
891	Maximizing User Engagement with Behavior Change Interventions. 2020 , 361-371	1
890	Cost-Effectiveness Evaluations of Behavior Change Interventions. 2020 , 372-384	
889	Addressing Underserved Populations and Disparities in Behavior Change. 2020 , 385-400	2
888	Behavior Change in Community Contexts. 2020 , 401-415	1
887	Changing Behavior in the Digital Age. 2020 , 416-429	
886	Critical and Qualitative Approaches to Behavior Change. 2020 , 430-442	2
885	Attitudes and Persuasive Communication Interventions. 2020 , 445-460	12
884	Management of hormone receptor-positive, HER2-negative early breast cancer. 2020 , 47, 187-200	8
883	Empleo actual de la hormonoterapia neoadyuvante en cáncer de mama: resultados de una encuesta realizada en España. 2020 , 33, 23-31	
882	Changing Behavior Using the Theory of Planned Behavior. 2020 , 17-31	25
881	Economic and Behavioral Economic Approaches to Behavior Change. 2020 , 617-631	
880	The Science of Behavior Change: The Road Ahead. 2020 , 677-699	3
879	Changing Behavior Using Control Theory. 2020 , 120-135	
878	Changing Behavior Using the Reflective-Impulsive Model. 2020 , 164-177	6
877	A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. 2020 , 20, 663	4
876	Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. 2020 , 18, 327	7
875	Exosomes and breast cancer drug resistance. 2020 , 11, 987	35

874	Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines. 2020 , 17, 970-985	2
873	Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells. 2020 , 12,	6
872	Currently Applied Molecular Assays for Identifying Mutations in Patients with Advanced Breast Cancer. 2020 , 21,	2
871	Development and Refinement of a Telehealth Intervention for Symptom Management, Distress, and Adherence to Adjuvant Endocrine Therapy after Breast Cancer. 2021 , 28, 603-618	2
870	Lysine in Combination With Estradiol Promote Dissemination of Estrogen Receptor Positive Breast Cancer Upregulation of U2AF1 and RPN2 Proteins. 2020 , 10, 598684	2
869	Resistance and Overcoming Resistance in Breast Cancer. 2020 , 12, 211-229	19
868	Targeting progesterone signaling prevents metastatic ovarian cancer. 2020 , 117, 31993-32004	9
867	Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. 2021 , 107, 1327-1335	5
866	Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients. 2020 , 184, 63-74	0
865	Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients. 2020 , 12, 771-781	1
864	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. 2020 , 38, 3273-3281	10
863	Self-Efficacy Interventions. 2020 , 461-478	7
862	Imagery, Visualization, and Mental Simulation Interventions. 2020 , 479-494	6
861	Affect-Based Interventions. 2020 , 495-509	0
860	Identification of a Six-lncRNA Signature With Prognostic Value for Breast Cancer Patients. 2020 , 11, 673	4
859	Optimized Polyethylene Glycolylated Polymer-Lipid Hybrid Nanoparticles as a Potential Breast Cancer Treatment. 2020 , 12,	9
858	A Role for Estrogen Receptor alpha36 in Cancer Progression. 2020 , 11, 506	9
857	CytoPAN-Portable cellular analyses for rapid point-of-care cancer diagnosis. 2020 , 12,	11

856	The significance of highlighting the oestrogen receptor low category in breast cancer. 2020 , 123, 1223-1227	7
855	Endocrine Therapy in Early Breast Cancer. 2020 , 15, 337-346	13
854	LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. 2020 , 11, 5513	38
853	Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer. 2020 , 61, 103047	3
852	Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. 2020 , 15, 235	6
851	Dual Tracers of $^{16}\text{[}^{18}\text{F]fluoro-}^{17}\text{Estradiol}$ and $^{18}\text{F]fluorodeoxyglucose}$ for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer. 2020 , 10, 580277	1
850	miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment. 2020 , 21,	7
849	Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model. 2020 , 40, 4869-4874	2
848	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. 2020 , 184, 783-795	1
847	Changing Behavior Using the Health Belief Model and Protection Motivation Theory. 2020 , 46-59	5
846	Changing Behavior Using the Common-Sense Model of Self-Regulation. 2020 , 60-76	3
845	Changing Behavior Using the Health Action Process Approach. 2020 , 89-103	19
844	Changing Behavior Using Self-Determination Theory. 2020 , 104-119	9
843	Changing Behavior Using the Transtheoretical Model. 2020 , 136-149	1
842	Changing Behavior Using Integrative Self-Control Theory. 2020 , 150-163	1
841	Changing Behavior Using Integrated Theories. 2020 , 208-224	11
840	Changing Behavior Using Theories at the Interpersonal, Organizational, Community, and Societal Levels. 2020 , 251-266	2
839	Autonomy-Supportive Interventions. 2020 , 510-522	3

838	Incentive-Based Interventions. 2020 , 523-536	1
837	Goal Setting Interventions. 2020 , 554-571	0
836	Planning and Implementation Intention Interventions. 2020 , 572-585	7
835	Self-Control Interventions. 2020 , 586-598	2
834	Habit Interventions. 2020 , 599-616	16
833	Dyadic Behavior Change Interventions. 2020 , 632-648	4
832	Social Identity Interventions. 2020 , 649-660	4
831	Motivational Interviewing Interventions. 2020 , 661-676	1
830	Index. 2020 , 700-708	
829	Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer. 2020 , 20, 446	1
828	Adjuvante endokrine Therapie beim primären Mammakarzinom. 2020 , 14, 27-42	
827	Validation of the Prognostic Stage of American Joint Committee on Cancer Eighth Edition Staging Manual in Invasive Lobular Carcinoma Compared to Invasive Ductal Carcinoma and Proposal of a Novel Score System. 2020 , 10, 1471	4
826	Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies. 2021 , 28, 1195-1211	1
825	Pregnancy in Breast Cancer Survivors. 2020 , 1252, 165-174	
824	Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer. 2020 , 14, 3535-3545	2
823	The Construction of Bone Metastasis-Specific Prognostic Model and Co-expressed Network of Alternative Splicing in Breast Cancer. 2020 , 8, 790	0
822	Diseases of the Breast during Pregnancy and Lactation. 2020 ,	0
821	Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients. 2020 , 184, 665-674	1

820	A review of clinical and emerging biomarkers for breast cancers: towards precision medicine for patients. 2020 , 1-14	
819	Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. 2020 , 12,	6
818	Monitoring Interventions. 2020 , 537-553	2
817	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. 2020 , 15, 608-618	3
816	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. 2020 , 383, 2557-2570	38
815	Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. 2020 , 12,	1
814	M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome. 2020 , 11, 560074	6
813	Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies. 2020 , 21, 1247-1264	2
812	The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. 2020 , 34, 1422-1438	9
811	Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers. 2020 , 10, 8188	2
810	Clinical Applications of Extracellular Vesicles in the Diagnosis and Treatment of Traumatic Brain Injury. 2020 , 37, 2045-2056	11
809	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. 2020 , 33, 2198-2207	9
808	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. 2020 , 20, 425	5
807	Clinicopathological Characteristics of Mutation and Amplification in Korean Patients with Breast Cancers. 2020 , 17, 1131-1135	2
806	Breast cancer: are long-term and intermittent endocrine therapies equally effective?. 2020 , 146, 2041-2049	3
805	Heregulin controls ER α and HER2 signaling in mammospheres of ER α -positive breast cancer cells and interferes with the efficacy of molecular targeted therapy. 2020 , 201, 105698	2
804	Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older. 2020 , 182, 355-365	8
803	Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma: Can We Learn From Breast Cancer?. 2020 , 49, 313-325	8

802	Adjuvant chemotherapy in small node-negative triple-negative breast cancer. 2020 , 135, 66-74	7
801	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. 2020 , 38, 2762-2772	39
800	Race May Not Impact Endocrine Therapy-Related Changes in Breast Density. 2020 , 29, 1049-1057	
799	Comparison between AJCC 8th prognostic stage and UICC anatomical stage in patients with primary breast cancer: a single institutional retrospective study. 2020 , 27, 1114-1125	
798	Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. 2020 , 18, 1257-1270	41
797	Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. 2020 , 6, 21	24
796	Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. 2020 , 9, 33	1
795	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. 2020 , 12,	3
794	A population-based analysis of breast cancer incidence and survival by subtype in Ontario women. 2020 , 27, e191-e198	11
793	The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer. 2020 , 27, 687-697	4
792	Evaluating the Age-Based Recommendations for Long-Term Follow-Up in Breast Cancer. 2020 , 25, e1330-e1338	
791	Could a Personalized Strategy Using Accelerated Partial Breast Irradiation be an Advantage for Elderly Patients? A Systematic Review of the Literature and Multidisciplinary Opinion. 2020 , 2020, 3928976	7
790	Adjuvant and neoadjuvant therapy for breast cancer. 2020 , 50, 225-229	26
789	Prognostic Value of Skeletal Muscle Depletion Measured on Computed Tomography for Overall Survival in Patients with Non-Metastatic Breast Cancer. 2020 , 23, 80-92	5
788	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. 2020 , 8,	28
787	Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. 2020 , 4,	15
786	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. 2020 , 26, 171-182	4
785	A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. 2020 , 180, 715-724	2

784	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo. 2020 , 15, 23	12
783	Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group. 2020 , 10, 4091	4
782	Immediate breast reconstruction surgery with expander/direct implant and use of acellular dermal matrix: Does hormone therapy increases the risk of infection?. 2020 , 65, 277-283	1
781	Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer. 2020 , 9, 35	1
780	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. 2020 , 16, 665-674	20
779	Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery. 2020 , 183, 145-151	4
778	Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?. 2020 , 29, R177-R185	
777	Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. 2020 , 66, 934-945	3
776	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. 2020 , 108, 661-670	9
775	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. 2020 , 14, 1179554920931816	2
774	Changing Behavior: A Theory- and Evidence-Based Approach. 2020 , 1-14	1
773	Long-term results from a series of patients managed with breast conservation surgery and hypofractionated radiotherapy in Christchurch: What is the recurrence rate and how do we detect recurrences. 2020 , 64, 852-858	
772	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. 2020 , 38, 1419-1428	37
771	Breast Cancer in Young Women. 2020 ,	1
770	Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries. 2020 , 147, 1437-1449	13
769	Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine. 2020 , 21, 112-119	20
768	Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients. 2020 , 20, 159-166	8
767	Women's coping strategies during the first three months of adjuvant endocrine therapy for breast cancer. 2020 , 7, 605-612	2

766	Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant). 2020 , 99, e19083	
765	Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. 2020 , 180, 777-790	10
764	Extended endocrine therapy in early breast cancer: how long and who for?. 2020 , 16, 4327-4336	2
763	Machine learning on genome-wide association studies to predict the risk of radiation-associated contralateral breast cancer in the WECARE Study. 2020 , 15, e0226157	10
762	A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer. 2020 , 39, 671-682	2
761	Development of an Immune-Related Prognostic Signature in Breast Cancer. 2019 , 10, 1390	19
760	Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. 2020 , 180, 735-745	2
759	Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group. 2020 , 244, 11-20	3
758	Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer. 2020 , 11, 320	45
757	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. 2020 , 38, 1346-1366	249
756	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. 2020 , 144, 545-563	82
755	S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis. 2020 , 317, 108965	7
754	Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis. 2020 , 44, 101706	12
753	Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence. 2020 , 40, 645-652	4
752	The Role of Glypican-1 in the Tumour Microenvironment. 2020 , 1245, 163-176	16
751	Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma. 2020 , 122, 1811-1817	4
750	Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer. 2020 , 9, 30	1
749	Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. 2020 , 15, e0231786	10

748	The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. 2020 , 12, 2491-2499	1
747	AMPK Activation by Metformin Promotes Survival of Dormant ER Breast Cancer Cells. 2020 , 26, 3707-3719	21
746	Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. 2020 , 15, e0231895	9
745	PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of and. 2020 , 80, 2230-2242	14
744	The Predictive Value of Early Changes in F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. 2020 , 25, 927-936	4
743	Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach. 2020 , 16, 1724-1736	4
742	New Advances in Molecular Breast Cancer Pathology. 2021 , 72, 102-113	13
741	Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. 2021 , 72, 114-122	9
740	Hypofractionated whole breast irradiation after IORT treatment: evaluation of acute toxicity and cosmesis. 2021 , 23, 179-182	2
739	GLUT1 participates in tamoxifen resistance in breast cancer cells through autophagy regulation. 2021 , 394, 205-216	6
738	Prognostic and predictive parameters in breast pathology: a pathologist's primer. 2021 , 34, 94-106	3
737	Axillary Management in Women with Early Breast Cancer and Limited Sentinel Node Metastasis: A Systematic Review and Metaanalysis of Real-World Evidence in the Post-ACOSOG Z0011 Era. 2021 , 28, 920-929	5
736	Treating Positive Axillary Disease in Elderly Breast Cancer Patients: The Impact of Age on Radiation Therapy. 2021 , 16, 276-282	1
735	Impact of patients' refusal to undergo adjuvant treatment measures on survival. 2021 , 185, 239-246	2
734	Anticancer medicinal plants used by Moroccan people: Ethnobotanical, preclinical, phytochemical and clinical evidence. 2021 , 266, 113435	18
733	Management of Early Stage Breast Cancer. 2021 ,	1
732	. 2021 , 5, pkaa084	1
731	Religion and spirituality: their role in the psychosocial adjustment to breast cancer and subsequent symptom management of adjuvant endocrine therapy. 2021 , 29, 3017-3024	5

730	Value of endometrial thickness in diagnosis of endometrial hyperplasia during selective estrogen receptor modulator therapy in premenopausal breast cancer patients. 2021 , 50, 101929	0
729	Nanotechnology-based drug delivery systems for the improved sensitization of tamoxifen. 2021 , 61, 102229	2
728	Endocrine Therapy for Breast Cancer. 2021 , 17, 177-181	
727	An evaluation of palbociclib as a breast cancer treatment option: a current update. 2021 , 22, 281-290	2
726	Bregman divergence to generalize Bayesian influence measures for data analysis. 2021 , 213, 222-232	1
725	The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability. 2021 , 162,	8
724	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. 2021 , 127, 700-708	0
723	Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre. 2021 , 74, 957-965	1
722	SAR439859, a Novel Selective Estrogen Receptor Degradator (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2021 , 20, 250-262	14
721	Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. 2021 , 20, 11-25	6
720	Molecular Drivers of Onco DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. 2021 , 39, 126-135	20
719	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. 2021 , 1875, 188459	2
718	Assessing Perceived Discrimination as Reported by Black and White Women Diagnosed with Breast Cancer. 2021 , 8, 589-595	3
717	miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers. 2021 , 28, 175-186	8
716	Obesity as potential breast cancer risk factor for postmenopausal women. 2021 , 8, 117-123	12
715	Symmetrization in Breast Reconstruction: Augmentation Procedures. 2021 , 413-424	
714	Nanotechnology advances in breast cancer. 2021 , 271-287	
713	Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. 2021 , 16, 484-490	0

712	Current Biomarkers for Precision Medicine in Breast Cancer. 2021 , 1187, 363-379	1
711	Hysteroscopic endometrial polypectomy in postmenopausal women. 2021 , 37, 55-60	
710	Silver nanoparticles achieve cytotoxicity against breast cancer by regulating long-chain noncoding RNA XLOC_006390-mediated pathway. 2021 , 10, 123-133	2
709	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. 2021 , 7, 2	3
708	Ultra-Short Fraction Schedules as Part of De-intensification Strategies for Early-Stage Breast Cancer. 2021 , 28, 5005-5014	2
707	Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review. 2021 , 28, 755-764	0
706	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. 2021 , 113, 1484-1494	22
705	Male Breast Cancer. 2021 , 643-656	
704	Perceived New Normal and Inner Strength on Quality of Life in Breast Cancer Patients Receiving Adjuvant Endocrine Therapy. 2021 , 8, 377-384	0
703	Chemoresistance in female-specific cancers and the associated anti-resistance therapies. 2021 , 49-69	
702	Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression. 2021 , 12, 610149	1
701	Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016. 2021 , 23, 24	7
700	Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients. 2021 , 1, 23-23	2
699	Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. 2021 , 27, 3576-3583	2
698	Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. 2021 , 124, 1503-1512	2
697	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. 2021 , 12,	4
696	Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions. 2021 , 14, 279-286	1
695	Regulation of tamoxifen sensitivity by the PLAC8/MAPK pathway axis is antagonized by curcumin-induced protein stability change. 2021 , 99, 845-858	5

694	Quality of Life (QoL) in Postmenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy. 1	1
693	A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. 2021 , 28, 684-697	
692	Dissection of Level III Axillary Lymph Nodes in Breast Cancer. 2021 , 13, 2041-2046	1
691	Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. 2021 , 187, 843-852	2
690	Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. 2021 , 13,	12
689	A novel signature predicts recurrence risk and therapeutic response in breast cancer patients. 2021 , 148, 2848-2856	0
688	Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. 2021 , 12, 733	12
687	In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. 2021 , 23, 17	5
686	Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art. 2021 , 13,	1
685	Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis. 2021 , 7, 289-301	3
684	MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. 2021 , 10, 19	16
683	Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer. 2021 , 11, 5566	1
682	Oncological outcomes of lipofilling in breast reconstruction: a matched cohort study with 250 patients. 2021 , 10, 914-923	1
681	Tamoksifen Kullanan Hastaların Jinekolojik Yaşından Değerlendirilmesi. 2021 , 30, 45-51	
680	Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. 2021 , 13,	5
679	Excess heart age in young breast cancer survivors over 2-year follow-up. 2021 , 32, 617-626	
678	Personalized Decision Making on Genomic Testing in Early Breast Cancer: Expanding the MINDACT Trial with Decision-Analytic Modeling. 2021 , 41, 354-365	
677	Characterization of estrogen receptor-low-positive breast cancer. 2021 , 188, 225-235	3

676	A novel metabolic gene signature-based nomogram to predict overall survival in breast cancer. 2021, 9, 367	2
675	Genetic Risk Stratification: A Paradigm Shift in Prevention of Coronary Artery Disease. 2021, 6, 287-304	6
674	Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice. 2021, 10,	2
673	The Emerging Role of Extracellular Vesicles in Endocrine Resistant Breast Cancer. 2021, 13,	4
672	Evaluation of the Effects of Tamoxifen on Adipose-Derived Stem Cells: A Pilot Study. 2021, 9, 555248	3
671	Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer. 2021, 26, e943-e953	6
670	ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer. 2021, 149, 200-213	1
669	Factors associated with late risks of breast cancer-specific mortality in the SEER registry. 2021, 189, 203-212	1
668	Estrogen Receptor Modulators. 1-74	
667	Risk factors for contralateral breast cancer in postmenopausal breast cancer survivors in the NIH-AARP Diet and Health Study. 2021, 32, 803-813	0
666	Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review. 2021, 30, 1262-1277	1
665	Endocrine therapy for cancer. 2021, 39, 208-214	
664	Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer. 2021, 28, 1472-1482	0
663	[Diffusion prophylactic axillary irradiation in breast cancer - Literature review]. 2021, 25, 191-199	
662	Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer. 2021, 28, 1087-1095	
661	MicroRNA Regulation of Breast Cancer Stemness. 2021, 22,	1
660	Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions. 2021, 13, 164-170	0
659	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. 2021, 127, 2545-2552	4

658	Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer. 2021 , 15, 69-84	1
657	Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review. 2021 , 23, 63	0
656	Genetic Testing and De-escalation of Contralateral Prophylactic Mastectomy. 2021 , 28, 4764-4766	1
655	Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. 2021 , 127, 2888-2894	2
654	Transcriptional control of parturition: insights from gene regulation studies in the myometrium. 2021 , 27,	1
653	Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells. 2021 , 187, 681-693	
652	The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies. 2021 , 20, 1163-1175	1
651	The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer. 2021 , 5,	9
650	Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. 2021 , 13,	1
649	Changes in Lactate Production, Lactate Dehydrogenase Genes Expression and DNA Methylation in Response to Tamoxifen Resistance Development in MCF-7 Cell Line. 2021 , 12,	3
648	: A Novel Tamoxifen Derivative Endowed with Antiestrogenic, Fluorescent, and Photosensitizer Properties. 2021 , 22,	0
647	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. 2021 , 28, 1803-1822	11
646	Traditional Korean medicine treatment for tamoxifen associated adverse events of breast cancer patient: A CARE - Compliant case report. 2021 , 43, 101378	1
645	The usefulness of biomarkers in diagnosis of asbestos-induced malignant pleural mesothelioma. 2021 , 40, 1817-1824	1
644	Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival. 2021 , 10, 3533-3544	
643	Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence. 2021 , 16, e0250967	2
642	Downregulation of SOX9 suppresses breast cancer cell proliferation and migration by regulating apoptosis and cell cycle arrest. 2021 , 22, 517	1
641	Obesity and Androgen Receptor Signaling: Associations and Potential Crosstalk in Breast Cancer Cells. 2021 , 13,	2

640	Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform. 2021 , 21, 487	0
639	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. 2021 , 41, 1-15	1
638	Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer. 2021 , 14, 3611-3624	
637	Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. 2021 , 12, 662734	2
636	Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. 2021 , 39, 1899-1908	10
635	Novel hybrid conjugates with dual estrogen receptor degradation and histone deacetylase inhibitory activities for breast cancer therapy. 2021 , 40, 116185	1
634	GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ER-positive breast cancer cells. 2021 , 13, 16178-16197	2
633	Selective estrogen receptor modulators and bone health. 2021 , 1-4	2
632	Evidence on Efficacy and Safety of Chinese Medicines Combined Western Medicines Treatment for Breast Cancer With Endocrine Therapy. 2021 , 11, 661925	0
631	Neuropilin-1: A feasible link between liver pathologies and COVID-19. 2021 , 27, 3516-3529	3
630	Comparing Local and Systemic Control between Partial- and Whole-Breast Radiotherapy in Low-Risk Breast Cancer-A Meta-Analysis of Randomized Trials. 2021 , 13,	4
629	Analysis of tamoxifen and its metabolites in dried blood spot and volumetric absorptive microsampling: comparison and clinical application. 2021 , 7, e07275	0
628	Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis. 2021 , 13,	4
627	Ibuprofen-derived fluorescence inhibitor of COX-2 for breast cancer imaging, prevention and treatment. 2021 , 190, 109326	1
626	Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial. 2021 , 4, e2114904	3
625	American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians. 2021 , 17, 234-238	3
624	Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen. 2021 ,	
623	Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. 2021 , 21, 707	

622	Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-PyMt mouse mammary tumours. 2021 , 21, 736	1
621	Breast Cancer Prevention: Time for Change. 2021 , 17, 709-716	6
620	Immunohistochemical Evaluation of FGD3 Expression: A New Strong Prognostic Factor in Invasive Breast Cancer. 2021 , 13,	4
619	rs12537 Is a Novel Susceptibility SNP Associated With Estrogen Receptor Positive Breast Cancer in Chinese Han Population. 2021 , 8, 708644	1
618	ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. 2021 , 10,	5
617	Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors. 2021 , 11, 681530	2
616	Adjuvant Photodynamic Therapy, Mediated via Topical Versus Systemic Administration of 5-Aminolevulinic Acid for Control of Murine Mammary Tumor after Surgical Resection. 2021 ,	
615	Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. 2021 , 22, e303-e313	26
614	European trends in breast cancer mortality, 1980-2017 and predictions to 2025. 2021 , 152, 4-17	10
613	Incidental axillary dose delivery to axillary lymph node levels I-III by different techniques of whole-breast irradiation: a systematic literature review. 2021 , 197, 820-828	1
612	Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. 2021 , 41, 968-980	4
611	De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough?. 2021 , 274, 654-663	2
610	Breast Cancer Mortality in the Americas and Australasia over the Period 1980-2017 with Predictions for 2025. 2021 , 10,	0
609	Machine Learning to Predict Tamoxifen Nonadherence Among US Commercially Insured Patients With Metastatic Breast Cancer. 2021 , 5, 814-825	0
608	Hormonoterapia adyuvante en c�ncer de mama. Revisi�n de la Evidencia y Abordaje Terap�utico en el Instituto Instituto Nacional de Cancerolog�a, Bogot�Colombia. 25, 130-141	
607	Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation. 2021 , 17, e1055-e1074	0
606	Phylogenetic analysis of combined lobular and ductal carcinoma of the breast. 2021 , 24,	1
605	F-fluorodeoxyglucose (FDG) PET or F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. 2021 , 23, 88	1

604	Breast Cancer Treatments: Updates and New Challenges. 2021 , 11,	16
603	Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). 2021 , 10, 6089-6098	1
602	Manejo actual de las metástasis vertebrales: un trabajo en equipo. 2021 , 62, e136-e142	
601	Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. 2021 , 301, 295-308	1
600	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. 2021 , 23, 83	3
599	Therapeutic Options in the Management of Aromatase Inhibitor-Associated Bone Loss. 2021 ,	1
598	Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data. 2021 , 21, e415-e426	3
597	The role of CDK4/6 inhibitors in early breast cancer. 2021 , 58, 160-169	5
596	Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy. 2021 , 33, 553-573	0
595	Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. 2021 , 32, 1410-1424	4
594	Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation. 2021 , 7, 104	4
593	The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis. 2021 , 58, 147-159	3
592	A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape. 2021 , 19, 398	0
591	Incident Type 2 Diabetes Risk of Selective Estrogen Receptor Modulators in Female Patients with Breast Cancer. 2021 , 14,	2
590	Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. 2021 , 15, 2051-2061	1
589	Real-world Evidence of Implementing eHealth Enables Fluent Symptom-based Follow-up of a Growing Number of Patients with Breast Cancer with the Same Healthcare Resources. 2021 ,	1
588	Nuclear Mechanisms Involved in Endocrine Resistance. 2021 , 11, 736597	3
587	Targeting steroid hormone receptors for anti-cancer therapy-A review on small molecules and nanotherapeutic approaches. 2021 , e1755	3

586	The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor-Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women. 2021 , 25, 196-205	0
585	A Survey of Potentially Modifiable Patient-Level Factors Associated with Self-Report and Objectively Measured Adherence to Adjuvant Endocrine Therapies After Breast Cancer. 2021 , 15, 2039-2050	0
584	Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. 2021 , 11, 700722	2
583	Expression Patterns of TOP2A and SIRT1 Are Predictive of Survival in Patients with High-Risk Soft Tissue Sarcomas Treated with a Neoadjuvant Anthracycline-Based Chemotherapy. 2021 , 13,	0
582	The clinical value of F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies. 2021 , 11, 3956-3965	2
581	B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein. 2021 , 11, 722828	3
580	Knockout of Calcyclin Binding Protein Impedes the Growth of Breast Cancer Cells by Regulating Cell Apoptosis and E-Catenin Signaling. 2021 , 40, 1317-1324	
579	Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. 2021 , 189, 653-663	0
578	Reducing Breast Cancer Incidence and Mortality: Rethinking an Approach to Risk Assessment and Prevention. 2021 , 17, 717-719	
577	Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study. 2021 , 110, 1613-1621	0
576	Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. 2021 , 162,	0
575	Lost but Not Least-Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer. 2021 , 13,	1
574	Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells. 2021 , 10,	2
573	Griffin: Framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA.	0
572	Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. 2021 , 59, 157-164	5
571	Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer. 2021 , 221, 113543	0
570	Luteolin mitigates tamoxifen-associated fatty liver and cognitive impairment in rats by modulating beta-catenin. 2021 , 908, 174337	1
569	Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study. 2021 , 59, 79-86	

568	Mucinous carcinoma in an octogenarian: Treatment and management of breast cancer in the elderly. 2021 , 16, 3201-3207	1
567	Breast diseases. 2022 , 289-322.e3	
566	Breast conservation among older patients with early-stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. 2021 , 127, 1749-1757	2
565	Reply to 'Intraoperative radiotherapy for breast cancer: powerful evidence to change practice'. 2021 , 18, 188-189	3
564	Principle of Radiation Therapy for Gynaecologic Cancers. 2021 , 655-661	
563	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. 2021 , 23, 1	14
562	Pharmacoeconomics and cost-effectiveness of treatments related to breast and cervix cancers. 2021 , 235-244	
561	The INTEND 1 randomized controlled trial of duct endoscopy as an indicator of margin excision in breast conservation surgery. 2021 , 186, 723-730	
560	Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: A systematic review. 2021 , 27, 100358	
559	Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer. 2021 , 11, e041626	3
558	Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. 2021 , 11, 415	3
557	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. 2021 , 15, 1178223421995854	
556	CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer. 2021 , 13, 4157-4181	11
555	Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. 2020 , 12, CD007245	3
554	Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen. 2018 , 7, 474-482	3
553	Clinical Applications of Circulating Tumor Cells in Breast Cancer. 2020 , 215, 147-160	4
552	Breast. 2017 , 589-636	59
551	A Novel Strategy to Improve Women's Health: Selective Estrogen Receptor Modulators. 2019 , 189-213	3

550	Androgen receptor expression inversely correlates with histological grade and N stage in ER/PgR male breast cancer. 2020 , 182, 55-65	0
549	Radiation and/or endocrine therapy? Recurrence and survival outcomes in women over 70 with early breast cancer after breast-conserving surgery. 2020 , 182, 411-420	5
548	Cancer of the Breast. 2014 , 1630-1692.e9	1
547	[Adjuvant endocrine therapy in premenopausal breast cancer: a initial dedicated counseling: can it be useful for better adherence?]. 2019 , 106, S28-S36	2
546	[Breast cancer management before 40 years: what change in one decade? A retrospective study at the "Institut de cancérologie de Lorraine": 2002-2012]. 2019 , 106, S60-S74	1
545	The Handbook of Behavior Change. 2020 ,	47
544	Cancer patients need better care, not just more technology. 2017 , 549, 325-328	29
543	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. 2021 , 113, 808-819	95
542	High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. 2020 , 31, 558-566	4
541	Single-cell Transcriptomics reveals multi-step adaptations to endocrine therapy.	1
540	Cellular Mechanisms of Oestrogen in Breast Cancer Development. 2015 , 3,	2
539	Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients. 2020 , 29, 582-590	2
538	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. 2020 , 5,	7
537	Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. 2018 , 128, 5603-5619	26
536	Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. 2020 , 22, 140	7
535	Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer. 2019 , 11, 16	20
534	Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. 2012 , 7, e36559	54
533	Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. 2013 , 8, e54078	10

532	The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women. 2013 , 8, e70890	6
531	Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. 2014 , 9, e88238	40
530	Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. 2014 , 9, e95629	25
529	Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race. 2014 , 9, e110281	6
528	Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. 2015 , 10, e0120832	17
527	Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China. 2015 , 10, e0125067	10
526	Fracture risk and adjuvant therapies in young breast cancer patients: a population-based study. 2015 , 10, e0130725	8
525	Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients. 2016 , 11, e0154386	3
524	National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China. 2016 , 11, e0162361	3
523	Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. 2017 , 12, e0171453	5
522	Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay. 2017 , 12, e0187679	3
521	Perspectives of pharmacogenetics approach to personalized tamoxifen therapy. 2017 , 1, 27-35	4
520	Update of the oxford overview: new insight and perspectives in the era of personalized medicine. 2012 , 71-9	1
519	Surveillance and Monitoring in Breast Cancer Survivors: Maximizing Benefit and Minimizing Harm. 2013 , e13-e18	1
518	Optimal management of the premenopausal patient with estrogen receptor-positive breast cancer. 2014 , e12-5	2
517	Lymph/angiogenesis contributes to sex differences in lung cancer through oestrogen receptor alpha signalling. 2019 , 26, 201-216	6
516	The effects of adjuvant endocrine therapy on bone health in women with breast cancer. 2019 , 241, R111-R124	18
515	High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer. 2020 , 12, 17079-17098	3

514	Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ER β positive breast cancer by up-regulation of ER α 2016 , 7, 56876-56888	27
513	Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor. 2016 , 7, 59809-59819	14
512	Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. 2016 , 7, 71235-71254	10
511	Receptor conversion in metastatic breast cancer: a prognosticator of survival. 2016 , 7, 71887-71903	27
510	Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. 2017 , 8, 74378-74390	14
509	Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. 2017 , 8, 100296-100311	18
508	mutation, reduced AKT serine 473 phosphorylation, and increased ER β serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer. 2018 , 9, 17711-17724	9
507	Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer. 2018 , 9, 26701-26710	10
506	FKBPL: a marker of good prognosis in breast cancer. 2015 , 6, 12209-23	9
505	The pioneer factor PBX1 is a novel driver of metastatic progression in ER β positive breast cancer. 2015 , 6, 21878-91	28
504	Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis. 2015 , 6, 39307-28	26
503	Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer. 2015 , 6, 44593-608	15
502	Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response. 2016 , 7, 38408-38426	6
501	alterations and metastasis in estrogen receptor positive breast cancer. 2019 , 5,	36
500	Transcription regulation of : a potential and novel therapeutic target in cancer. 2018 , 6, 443	18
499	Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. 2018 , 30, 605-612	13
498	Three-Dimensional Manufactured Supports for Breast Cancer Stem Cell Population Characterization. 2019 , 20, 839-851	3
497	Structure Guided Molecular Docking Assisted Alignment Dependent 3DQSAR Study on Steroidal Aromatase Inhibitors (SAIs) as Anti-breast Cancer Agents. 2019 , 16, 808-817	10

496	EHealth Acceptance and New Media Preferences for Therapy Assistance Among Breast Cancer Patients. 2016 , 2, e13	17
495	Smartphone-Enabled Health Coaching Intervention (iMOVE) to Promote Long-Term Maintenance of Physical Activity in Breast Cancer Survivors: Protocol for a Feasibility Pilot Randomized Controlled Trial. 2017 , 6, e165	20
494	Special considerations of breast cancer management in the elderly. 2020 , 9, BMT46	2
493	Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic. 2020 , 14, 1027	9
492	Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review. 2020 , 13,	6
491	Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer. 2019 , 13, 24-28	1
490	Nodal staging affects adjuvant treatment choices in elderly patients with clinically node-negative, estrogen receptor-positive breast cancer. 2020 , 27, 250-256	1
489	Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis. 2019 , 7, 690-695	4
488	Protein- and growth-modulatory effects of carcinoma-associated fibroblasts on breast cancer cells: Role of interleukin-6. 2020 , 56, 258-272	4
487	Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer. 2020 , 12, 415-420	2
486	Curcumin attenuates lncRNA H19-induced epithelial-mesenchymal transition in tamoxifen-resistant breast cancer cells. 2021 , 23,	13
485	Hormonal therapies in young breast cancer patients: when, what and for how long?. 2013 , 5 Suppl 1, S36-46	16
484	The Role of Long Noncoding RNAs in Antiestrogen Resistance in Breast Cancer: An Overview and Update. 2020 , 23, 129-140	6
483	Coronary Event Analysis in Breast Cancer Patients Who Received Breast-Conserving Surgery and Post-Operative Radiotherapy: a Korean Nationwide Cohort Study. 2020 , 23, 291-302	2
482	Adjuvant hormonal therapy in premenopausal women with breast cancer. 2015 , 36, 195-200	3
481	The recurrence frequency of breast cancer and its prognostic factors in Iranian patients. 2017 , 7, 40-43	4
480	Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. 2018 , 7, 96-101	4
479	Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan. 2020 , 32, 175-180	3

478	Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23). 2017 , 49, 739-747	17
477	Diffusion-Weighted Imaging of Breast Cancer: Correlation of the Apparent Diffusion Coefficient Value with Pathologic Prognostic Factors. 2019 , 15, 262-267	2
476	Ipsilateral breast tumor recurrence in early stage breast cancer patients treated with breast conserving surgery and adjuvant radiation therapy: Concordance of biomarkers and tumor location from primary tumor to in-breast tumor recurrence. 2020 , 11, 20-30	2
475	Predictive markers of endocrine response in breast cancer. 2018 , 8, 1-7	14
474	Assessing the impact of socio-economic variables on breast cancer treatment outcome disparity. 2013 , 14, 7133-6	6
473	Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. 2014 , 15, 9233-9	10
472	Breast cancer: major risk factors and recent developments in treatment. 2014 , 15, 3353-8	79
471	Pre-treatment Elevated Platelet Count Associates with HER2 Overexpression and Prognosis in Patients with Breast Cancer. 2015 , 16, 5537-40	13
470	Differences in Prognostic Factors between Early and Late Recurrence Breast Cancers. 2015 , 16, 6575-9	5
469	The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies. 2020 , 9,	13
468	Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients. 2017 ,	6
467	Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer. 2019 , 7, e7976	10
466	Limitations of Personalized Medicine and Gene Assays for Breast Cancer. 2017 , 9, e1100	6
465	Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review. 2015 , 7, e364	11
464	Safety and Effectiveness of F-18 Fluoroestradiol Positron Emission Tomography/Computed Tomography: a Systematic Review and Meta-analysis. 2021 , 36, e271	1
463	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. 2021 , OP2100482	1
462	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. 2021 , 99, 1691-1710	2
461	Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients. 2021 , 13,	0

- 460 Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. **2021**, 10, CD013091 2
- 459 Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells. **2021**, 9, e12124 2
- 458 Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines. **2021**, 1 1
- 457 Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. **2021**, 1 1
- 456 Lactate and pyruvate levels correlation with lactate dehydrogenase gene expression and glucose consumption in Tamoxifen-resistant MCF-7 cells using capillary electrophoresis with contactless conductivity detection (CE-C D). **2021**, 0
- 455 Tratamiento del cáncer de mama infiltrante localizado: nuevos desafíos. **2021**, 57, 1-20
- 454 The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. **2021**, 6, 100289 3
- 453 Behandlung des Mammakarzinoms. **2012**, 34,
- 452 Controversies in adjuvant endocrine therapy for breast cancer. **2012**, 20-6 1
- 451 Tamoxifen and Raloxifene Head to Head: The STAR Trial. **2013**, 135-142
- 450 Chemoprevention: Cinderella Waiting for the Ball. **2013**, 115-134 1
- 449 Systemic Treatment of Breast Cancer and Breast Reconstruction. **2013**, 91-95
- 448 A Case of Recurrent Breast Cancer with Carcinomatous Meningitis at 10 Years after Resection, Manifested by Rapid Exacerbation. **2013**, 74, 1208-1211
- 447 Carcinogenesis and Tamoxifen. **2013**, 101-114
- 446 Acquis et limites de l'hormonothérapie adjuvante. **2013**, 113-118
- 445 Adjuvant Therapy: The Breakthrough. **2013**, 69-84 1
- 444 Mammakarzinom. **2013**, 625-705
- 443 Effects of femara and tamoxifen on proliferation of FM3A cells in culture. **2013**, 14, 2819-22 2

- 442 Ductal Carcinoma In Situ of the Breast. **2014**, 269-311 1
- 441 Systemic Therapy. **2014**, 381-420
- 440 Microvesicular Transfer of MicroRNA in Tumor Microenvironment. **2014**, 327-348
- 439 The role of adjuvant systemic therapy in patients with operable breast cancer. **2014**, 199-218
- 438 Breast Cancer. **2014**, 379-384 1
- 437 Atypical endometrial hyperplasia arising in an endometrial polyp in a tamoxifen-treated breast cancer patient in whom endometrial cytology was negative for cancer^|^mdash;A case report^|^mdash;. **2014**, 53, 318-322
- 436 Adjuvant Therapy for Breast Cancer: Hormonal Therapy. **2015**, 353-362
- 435 Early Breast Cancers. **2015**, 61-112
- 434 The Emerging Role of Prophylactic Mastectomy. **2015**, 129-136
- 433 Multimodale Therapie des nicht metastasierten Mammakarzinoms. **2015**, 157-169
- 432 Hormonal Therapy in Nonmetastatic Breast Cancer. **2015**, 339-344
- 431 Factors Influencing the Background Parenchymal Enhancement in Follow-Up Breast MRI after Adjuvant Endocrine Therapy. **2015**, 19, 99
- 430 Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care. **2015**, 101-114
- 429 Translation: Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. **2015**, 5, 44
- 428 Breast cancer and neutropenic sepsis. **2015**, 1-10
- 427 ROLE OF ESTROGEN RECEPTOR BETA IN THE DEVELOPMENT AND TREATMENT OF BREAST CANCER. **2015**, 14, 39-46 1
- 426 Mammakarzinom der Frau. **2016**, 201-276
- 425 Breast-Conserving Therapy: Hypofractionated and Conventional Whole-Breast Irradiation and Accelerated Partial-Breast Irradiation. **2016**, 233-247

424 Adjuvant Systemic Therapy: Endocrine Therapy. **2016**, 99-130

423 Metastatic Breast Cancer. **2016**, 451-474

422 Genomic Markers in ER-Negative Breast Cancer. **2016**, 283-298

421 Carcinome canalaire infiltrant d'utérus. **2016**, 145-149

420 Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. **2016**, 1-21

419 Breast Brachytherapy: Permanent Breast Seed Implants [How and Why?]. **2016**, 185-196

418 Second Primary Neoplasms Following a Diagnosis of Breast Cancer. **2016**, 213-234

417 Systemic Therapy. **2016**, 335-390

416 Thinking Small: Circulating microRNAs as Novel Biomarkers for Diagnosis, Prognosis, and Treatment Monitoring in Breast Cancer. **2016**, 221-242

415 Facteurs prédictifs de réponse au traitement. **2016**, 57-59

414 Breast Cancer. **2016**, 433-446

413 Breast Cancer in Younger Women. **2016**, 529-564

412 Endocrine Therapy. **2016**, 67-82

411 A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy. **2016**, 8, e555

410 Pharmacogenomics of Tamoxifen. **2016**, 265-277

409 Induction of c-Jun Expression by Breast Cancer Anti-estrogen Resistance-3 (BCAR3) in Human Breast MCF-12A Cells. **2016**, 26, 1383-1391

408 Mammatumoren. **2017**, 419-444

407 Concurrent Use of Radiation Therapy and Targeted Molecules in the Breast Cancer Treatment. **2017**, 645-653

- 406 Pharmacological Therapy for Vasomotor Symptoms in Breast Cancer Survivors. **2017**, 255-272
- 405 Breast Cancer in Elderly Women. **2017**, 1-25 ○
- 404 Mammakarzinom bei der alten und geriatrischen Patientin. **2017**, 1-16
- 403 Pharmacogenomics of Tamoxifen. **2017**, 265-277
- 402 Tamoxifen: An Update. **2018**, 291-299
- 401 Uncovering genomic trajectories with heterogeneous genetic and environmental backgrounds across single-cells and populations. 1
- 400 Inflammatory Breast Cancer Outcomes in a Contemporary Series. **2017**, 37, 5057-5063 2
- 399 Prognostic Value of Estrogen and Progesterone Receptor Expression in Low Proliferative Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. **2017**, 5, 64-70
- 398 Mammakarzinom bei der alten und geriatrischen Patientin. **2018**, 401-416
- 397 Adverse effects of adjuvant endocrine therapy. **2018**, 64-69 1
- 396 Adjuvant Endocrine Therapy for Breast Cancer. **2019**, 413-432
- 395 Cancer in the Very Elderly and Management. **2019**, 177-188
- 394 A Novel Melatonergic Signature Predicts Recurrence Risk and Therapeutic Response in Breast Cancer Patients.
- 393 Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor. **2019**, 97, 223-229 ○
- 392 Les modulateurs sélectifs des récepteurs aux Œstrogènes : Œ propos de deux exemples. **2019**, 197-207
- 391 Learning Hormonal Therapy Medication Adherence from an Online Breast Cancer Forum. **2019**, 233-257
- 390 Systemic Treatment of Breast Cancer and Breast Reconstruction. **2019**, 763-767
- 389 Oncofertility Consults in the REI Setting. **2019**, 289-295

- 388 Adjuvant Systemic Therapy: Endocrine Therapy. **2019**, 103-127
- 387 The Conundrum of Dual Primary Malignancies: Four Years' Experience of a Single Tertiary Care Institute in India. **2019**, 40, 521
- 386 Prognostic and Predictive Factors. **2019**, 163-172
- 385 Pharmacogenomics. **2019**, 175-192
- 384 Correlation of radiotherapy with prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping. **2019**, 31, 471-480 1
- 383 Breast-Conserving Therapy: Hypofractionated and Conventional Whole-Breast Irradiation and Accelerated Partial-Breast Irradiation. **2019**, 209-219
- 382 Machine Learning Methods to Identify Genetic Correlates of Radiation-Associated Contralateral Breast Cancer in the WECARE Study.
- 381 Analysis of DCE-MRI features in tumor for prediction of the prognosis in breast cancer. **2019**,
- 380 Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports. **2019**, 21, 24-30
- 379 Predictive Cancer Biomarkers. **2019**, 383-393
- 378 Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?. **2019**, 11, e5417 1
- 377 Endocrine therapy use and the risk of cardiovascular disease in postmenopausal breast cancer survivors: two cohort studies in the UK and US.
- 376 Impact of Systemic Anticancer Therapy on Fertility. **2020**, 67-80
- 375 The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies.
- 374 RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer. **2020**, 19, 52-60 3
- 373 Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
- 372 Is the extension of adjuvant hormone therapy for breast cancer justified?. **2020**, 74-79
- 371 ABSI □The Voice for Breast Surgery in India; Celebrating 10 positively eventful years! (2011 □2021). 1

370 Systemic Staging (Total Body [When, How). **2022**, 297-305

369 PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer. **2020**, 11, 4722-4734 1

368 New opportunities of pharmacogenetics approach to personalized tamoxifen therapy (updated systematic review). **2020**, 42-56

367 Hormone Receptor Expression on Endocrine Therapy in Patients with Breast Cancer: A Meta-Analysis. **2020**, 3134820972327 1

366 Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. **2021**, 31, 222-231 0

365 Endoxifen and fulvestrant regulate estrogen-receptor β and related DEADbox proteins. **2020**, 9, 1156-1167 0

364 Breast cancer: Emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.

363 Effect of Adjuvant Hormonal Therapy on the Development of Pulmonary Fibrosis after Postoperative Radiotherapy for Breast Cancer. **2020**, 23, 449-459 2

362 Breast Cancer with IgA Vasculitis due to Endocrine Therapy in an Elderly Female Undergoing Postoperative Case Report **2020**, 81, 1266-1272

361 Radiation therapy for the elderly-change of concepts in breast cancer?. **2020**, 9, S131-S138

360 Breast Cancer Diagnosis and Management. **2020**, 313-328

359 Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer. **2020**, 16, 17-22 1

358 Cardio-Oncology: Preventing Broken Hearts in Women with Breast Cancer. **2020**, 217-236

357 Breast Cancer in Elderly Women. **2020**, 967-990

356 Endocrine Treatment of Young Patients with EBC. **2020**, 113-126

355 AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells.

354 Correlation between Cancer Breast Subtypes and Age at Presentation in Egyptian Patients; Single Institution Experience. **2020**, 11, 26-34

353 Maligne Tumoren der Mamma. **2020**, 385-402

- 352 Wirkung und Nebenwirkung von Krebstherapien. **2020**, 51-101
- 351 Supervised machine learning model to predict oncotype DX risk category in patients over age 50. **2021**, 1 0
- 350 Current Status and Problems of Breast Cancer Treatment with Schizophrenia. **2021**, 0
- 349 The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis. **2021**, 9
- 348 LYN kinase and estrogen receptor ER β involvement in carcinogenesis and potential therapeutic target for tumors. **2021**, 8, 44-59
- 347 Prädiktive und prognostische Faktoren in der Therapie des frühen Mammakarzinoms. **2021**, 27, 1175
- 346 Adjuvant Endocrine Therapy in Early Breast Cancer. **2021**, 165-177
- 345 Hypothalamic estrogen receptor alpha mediates key side effects of tamoxifen therapy in mice.
- 344 Multi-compartment tumor organoids. 0
- 343 Genetic Mutations Associated with Hormone-Positive Breast Cancer in Ethiopian Women.
- 342 ESR1 mutation as potential predictive marker for choice of treatment tactics in hormone-resistant HR+/HER2-negative breast cancer. **2020**, 68-73
- 341 The Whole View of Therapies for Breast Cancer. **2020**,
- 340 Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. **2013**, 4, 35-48 6
- 339 Gene expression profiling in breast cancer. **2013**, 5, 132-8 9
- 338 Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. **2014**, 71, 1549 12
- 337 Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials. **2014**, 7, 3333-43 8
- 336 Project for the National Program of Early Diagnosis of Endometrial Cancer Part I. **2015**, 8, 305-14 8
- 335 Does estrogen receptor determination affect prognosis in early stage breast cancers?. **2015**, 8, 21454-9 9

334	Adjuvant endocrine therapy in premenopausal women with breast cancer. 2015 , 13, 663-72	12
333	Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. 2016 , 8, 3585-92	11
332	Immune Mediator Pharmacogenomics: SNPs and Estrogen-Dependent Regulation of Inflammation. 2017 , 3,	1
331	Endocrine Therapy for Early Breast Cancer: Updated Review. 2017 , 17, 405-411	33
330	Talking About My Care: Detecting Mentions of Hormonal Therapy Adherence Behavior in an Online Breast Cancer Community. 2017 , 2017, 1868-1877	5
329	Genomic Testing in the Management of Early-Stage Breast Cancer. 2017 , 24, 229-238	1
328	It's not an easy fix: Adherence to adjuvant endocrine therapy after breast cancer. 2021 , 31, 221-227	
327	. 2021 , 31, 228-234	
326	Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. 2021 , 1	3
325	Importance of medication reconciliation in cancer patients. 2021 , 14, 98	1
324	Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement. 2021 , 13,	3
323	Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics. 2021 , 11, 738222	
322	Endometrial Surveillance in Tamoxifen and Letrozole Treated Breast Cancer Patients.. 2021 , 13, e20030	
321	Copy number heterogeneity identifies ER+ breast cancer patients with adverse outcome after adjuvant endocrine therapy.	
320	Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients.. 2021 , 12, 661443	1
319	The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer.. 2021 , 11, 759595	0
318	Towards Personalized Nutrition Applications with Nutritional Biomarkers and Machine Learning. 2022 , 73-122	2
317	Therapiealgorithmen für das Mammakarzinom. 2021 , 27, 1165-1174	

- 316 Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. **2021**, 1
- 315 Adjuvant abemaciclib for high-risk breast cancer: the story continues. **2021**, 32, 1457-1459 0
- 314 Research Progress on Clinical Features and Related Treatment of Senile Breast Cancer. **2021**, 11, 5613-5619
- 313 Recurrencia y características clínicas patológicas en los grupos de riesgo establecidos por Oncotype Dx, original y TAILORx, en cáncer de mama temprano. **2021**, 66, 263-272
- 312 Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study.. **2021**, 20, 15347354211063791
- 311 A Case of Metastatic Spinal Tumor from Progressive Breast Cancer Detected as a Pathological Fracture. **2021**, 35, 203-207
- 310 ART in Cancer Survivors. **2022**, 47-66
- 309 Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis.. **2022**, 24, e1 1
- 308 High BRCA1 gene expression increases the risk of early distant metastasis in ER breast cancers.. **2022**, 12, 77 0
- 307 Improving the Therapeutic Ratio Among Older Women With Early Stage Breast Cancer by Reevaluating Adjuvant Radiation Therapy and Hormone Therapy.. **2022**, 112, 52-55 0
- 306 Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.. **2022**, 1
- 305 Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.. **2022**, 12, 1
- 304 A new strategy: long-term adjuvant tamoxifen treatment and other discoveries at the University of Leeds. **2022**, 47-65
- 303 Recurrent Breast Cancer (Local and Metastatic): Surgical Aspects. **2022**, 339-351
- 302 Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer.. **2022**, 12, 1643
- 301 Geospatial Disparities in the Treatment of Curable Breast Cancer Across the US.. **2022**, 1
- 300 Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort.. **2022**, 0
- 299 Tumour Markers, Prognostic and Predictive Factors in Breast Cancer. **2022**, 221-241 1

298	Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC).. 2021 , 11, 798296	2
297	gene as a biomarker for targeting triple negative breast cancer in presence of Rapamycin.. 2022 , 41, 166-182	0
296	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.. 2022 , JCO2102019	4
295	Association between antidepressant use and second breast cancer event after ductal carcinoma in situ diagnosis: a nested case-control study.. 2022 , 33, 593	
294	Updates on breast biomarkers.. 2022 , 480, 163	6
293	Selective serotonin reuptake inhibitors associated with increased mortality risk in breast cancer patients in Northern Israel.. 2022 ,	0
292	RSK-Mediated Non-canonical Activation of EphA2 by Tamoxifen.. 2022 , 45, 162-168	1
291	Rationale and usability findings of an e-health intervention to improve oral anticancer adherence among breast cancer survivors: The My Journey mindfulness study.. 2022 , 26, 100898	2
290	Rapid Reductions in Breast Density following Tamoxifen Therapy as Evaluated by Whole-Breast Ultrasound Tomography.. 2022 , 11,	0
289	Curative Treatment for Non-Metastatic Breast Cancer in Sub-Saharan Africa: Guideline Concordance, Initiation, and Abandonment in the Prospective ABC-DO Cohort.	
288	Knockdown of ATG4A inhibits breast cancer progression and promotes tamoxifen chemosensitivity by suppressing autophagy.. 2022 , 25,	0
287	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. 2022 , 1	0
286	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.. 2022 ,	7
285	Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.. 2022 , 1	0
284	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches.. 2021 , 11, 667397	1
283	Breast cancer: presentation, investigation and management.. 2022 , 83, 1-7	8
282	NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.. 2022 , 12, 1972	1
281	New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling. 2021 , 11, 5214-5232	1

- 280 ECSIT inhibits cell death to increase tumor progression and metastasis via p53 in human breast cancer.. **2022**, 11, 699-709 ○
- 279 Strategies to mitigate the toxicity of cancer therapeutics. **2022**, ○
- 278 Endometrium Kanseri Nedeniyle Opere Edilen Olgunun Joyce Travelbee'nin ~ İsan ~ İsana ~ Ökiler Modeli ile Ge ~ İncelenmesi. ○
- 277 Leucopenia induced by tamoxifen in a breast cancer patient: a case report. **2022**, 30, 8-10 1
- 276 Retinoids. **2022**, 439-453 ○
- 275 Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.. **2022**, 14, 17588359221081075 1
- 274 Sharing individual participant data: through a systematic reviewer lens.. **2022**, 23, 167 2
- 273 Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer.. **2022**, 14, ○
- 272 A Review of Biosensors for Detecting Tumor Markers in Breast Cancer.. **2022**, 12, ○
- 271 Validity of 1% Hormonal Receptor Positivity Cutoff by the ASCO/College of American Pathologists Guidelines at the Georgia Cancer Center.. **2022**, 6, e2100201 ○
- 270 De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.. **2022**, ○
- 269 Genetic and epigenetic driven variation in regulatory regions activity contribute to adaptation and evolution under endocrine treatment. ○
- 268 Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan.. **2022**, 1 ○
- 267 Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis.. **2022**, 13, 760514 1
- 266 Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer.. **2022**, 20, 9 ○
- 265 A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies.. **2022**, 14, ○
- 264 Discovery of Thieno[2,3-]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degradable with Highly Improved Antitumor Effect and Favorable Druggability.. **2022**, ○
- 263 Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.. **2022**, 12, 813462 ○

262	The Role of Safety-Net Hospitals in Reducing Disparities in Breast Cancer Care.. 2022 , 1	1
261	Documenting patients' and providers' preferences when proposing a randomized controlled trial: a qualitative exploration.. 2022 , 22, 64	
260	Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Genes Signature.. 2022 ,	1
259	CCDC134 as a Prognostic-Related Biomarker in Breast Cancer Correlating With Immune Infiltrates.. 2022 , 12, 858487	0
258	Late Recurrence Following Early Breast Cancer.. 2022 , JCO2200167	0
257	Diethylhexyl Phthalate and Bisphenol A Promote Vincristine and Tamoxifen Resistance .. 2022 ,	
256	Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer. 2022 , 2022, 1-14	1
255	Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study.. 2022 , 12, 5489	2
254	Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease?. 2022 , 14, e22804	
253	Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.. 2022 ,	7
252	Tamoxifen \square Lieferengpass: Eine Stellungnahme der Fachgesellschaft. 2022 , 19, 26-29	
251	Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA.. 2022 , 193, 161	0
250	Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions.. 2022 , 10,	2
249	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer.. 2022 ,	
248	Adjuvant Hormone Therapy-Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis.. 2022 , 1-7	
247	A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis.. 2022 ,	0
246	Application of Personal Health Record in Enhancing the Quality of Life in Patients With Breast Cancer Who Received Adjuvant Hormonal Therapy.. 2022 , 18, 155-162	
245	Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.. 2022 , 105, 102375	4

244	Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials.. 2022 , 22, 98	0
243	16β18F-fluoro-17βFluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer.. 2022 ,	3
242	Knockdown of YAP/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells.. 2022 , 601, 73-78	0
241	Berlin, im Februar 2022 □ Tamoxifen-Lieferengpass: Eine Stellungnahme der Fachgesellschaft. 2022 , 82, 376-379	
240	An intervention mapping-based support program that empowers patients with endocrine therapy management.. 2022 , 92, 102071	0
239	Association between medication adherence and non-drug healthcare utilisation and costs: a retrospective longitudinal cohort study among US women age 65 and older. 2021 , 11, e052146	
238	Identification of key genes involved in tamoxifen-resistant breast cancer using bioinformatics analysis.. 2021 , 10, 5246-5257	0
237	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics.. 2021 ,	1
236	Systemtherapie beim Mammakarzinom. 2022 , 28, 77-90	
235	Current status of AYA-generation breast cancer: trends worldwide and in Japan.. 2021 , 27, 16	
234	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.. 2022 , 14,	1
233	'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.. 2022 , 9, 783494	0
232	Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.. 2022 , 1	1
231	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2-Early Breast Cancer.. 2022 , JCO2102759	2
230	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation.. 2022 , 8, 53	0
229	LINC00355 regulates p27 expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.. 2022 , 8, 49	0
228	FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer.. 2022 , 234, 153898	3
227	Data_Sheet_1.ZIP. 2020 ,	

226 Image_1.TIF. 2020,

225 Image_10.TIF. 2020,

224 Image_11.TIF. 2020,

223 Image_2.TIF. 2020,

222 Image_3.TIF. 2020,

221 Image_4.TIF. 2020,

220 Image_5.TIF. 2020,

219 Image_6.TIF. 2020,

218 Image_7.TIF. 2020,

217 Image_8.TIF. 2020,

216 Image_9.TIF. 2020,

215 Table_1.DOCX. 2020,

214 Table_2.DOCX. 2020,

213 Table_3.DOCX. 2020,

212 Table_4.DOCX. 2020,

211 Data_Sheet_1.docx. 2020,

210 Table_1.xlsx. 2020,

209 Image_1.jpeg. 2019,

208 Image_2.jpeg. 2019,

207 Table_1.docx. 2019,

206 Table_2.docx. 2019,

205 Table_3.docx. 2019,

204 Table_1.XLSX. 2020,

203 Table_2.XLSX. 2020,

202 Table_3.XLSX. 2020,

201 data_sheet_1.PDF. 2018,

200 Data_Sheet_1.docx. 2020,

199 Image_1.tif. 2020,

198 Table_1.docx. 2020,

197 DataSheet_1.xlsx. 2020,

196 DataSheet_2.xlsx. 2020,

195 DataSheet_3.docx. 2020,

194 Table_1.DOCX. 2019,

193 DataSheet_1.docx. 2020,

192 Table_1.docx. 2020,

191 DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer.. 2022, 1

1

190	Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.. 2022 , 21, 15330338221090351	1
189	Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes.. 2021 , 7, 130-135	
188	EGFR inhibition reverses epithelial-mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells.. 2022 , 47,	0
187	Research Progress of Estrogen Receptor-Low Positive in Breast Cancer. 2022 , 12, 3344-3349	
186	Co-development of a text messaging intervention to support adherence to adjuvant endocrine therapy in women with breast cancer: A mixed-methods approach (Preprint).	0
185	Accelerated partial breast irradiation (APBI).. 2022 ,	
184	Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study.. 2022 ,	
183	Eating Earlier And More Frequently Is Associated With Better Diet Quality In Female Brazilian Breast Cancer Survivors Using Tamoxifen.. 2022 ,	1
182	Association between tumor F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.. 2022 , 12, 7858	0
181	A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.. 2022 , 128 Suppl 11, 2209-2223	0
180	Relationship of Breast Cancer with Other Hormone-Sensitive Cancers. 2022 , 47-71	
179	The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review. 2022 ,	1
178	Treatment of Breast Cancer in Young Adults.. 2022 , 42, 1-12	2
177	Field carcinogenesis and biological significance of the potential of the bystander effect: carcinogenesis, therapeutic response, and tissue regeneration.. 2022 ,	
176	Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred.. 2022 , 12, 8097	1
175	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.. 2022 ,	
174	Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.. 2022 ,	
173	The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.. 2022 ,	0

- 172 The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute. **2022**, 2022, 1-9 0
- 171 Concepts in Breast Surgery. **2022**, 907-919
- 170 Discovery of Fused Benzimidazole-Imidazole Autophagic Flux Inhibitors for Treatment of Triple-Negative Breast Cancer.
- 169 Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor Positive Breast Cancer. **2022**, 1-13 0
- 168 Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database. 1
- 167 Breast Cancer Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). **2022**, 14, 2569 7
- 166 Adherence to oral hormonal anticancer agents in breast cancer. 030089162210961
- 165 Tamoxifen Increased Parasite Burden and Induced a Series of Histopathological and Immunohistochemical Changes During Chronic Toxoplasmosis in Experimentally Infected Mice. **2022**, 13, 1
- 164 EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. **2022**, 23, 6122 0
- 163 BARD1 mystery: tumor suppressors are cancer susceptibility genes. **2022**, 22, 2
- 162 LINC00094/miR-19a-3p/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway. 1
- 161 Gypensapogenin H suppresses tumor growth and cell migration in triple-negative breast cancer by regulating PI3K/AKT/NF- κ B/MMP-9 signaling pathway. **2022**, 126, 105913 1
- 160 Update on prognostic and predictive biomarkers of breast cancer. **2022**, 0
- 159 Hydrogel Stamping for Rapid, Multiplexed, Point-of-Care Immunostaining of Cells and Tissues. **2022**, 14, 27613-27622 1
- 158 Improving Adherence to Adjuvant Endocrine Therapy in Sub-Saharan Africa: Challenges and Innovative Nurse-Driven Solutions. 0
- 157 Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. Publish Ahead of Print,
- 156 Recent insights into the effects of metabolism on breast cancer cell dormancy. 0
- 155 The Effect of Estrogen Receptor Status on Survival in Breast Cancer Patients in Ethiopia. Retrospective Cohort Study. Volume 14, 153-161

- 154 A potent estrogen receptor and microtubule specific purine-benzothiazole-based fluorescent molecular probe induces apoptotic death of breast cancer cells. **2022**, 12, 1
- 153 Preventing late recurrence in hormone receptor-positive early breast cancer: a review. **2022**, 172, 53-64
- 152 Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation.
- 151 Tools for Contralateral Prophylactic Mastectomy Decision Making. 1
- 150 Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer.
- 149 Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer: A Literature Review. **2022**, 29, 4956-4969 0
- 148 Characterizing clinicopathologic features of estrogen receptor-positive/progesterone receptor-negative breast cancers. **2022**, 1
- 147 Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer: Impact on patient anxiety and cancer detection. **2022**, 22, 0
- 146 From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. **2022**, 14, 3469 1
- 145 Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. 13,
- 144 Natural products derived from medicinal plants and microbes might act as a game-changer in breast cancer: a comprehensive review of preclinical and clinical studies. 1-45 1
- 143 Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial. 2
- 142 Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer. **2022**, 240, 114565 0
- 141 Perioperative Care of the Cancer Patient: Breast Procedures. **2023**, 262-281
- 140 Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial. 1
- 139 Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.
- 138 An Overview of Breast Cancer Therapy. **2022**, 242-258
- 137 Radiotherapy in Carcinoma Breast. **2022**, 219-241

- 136 Intra-Operative Electron Radiation Therapy: An Update of the Evidence Collected in 40 Years to Search for Models for Electron-FLASH Studies. **2022**, 14, 3693
- 135 Protective effect of luteolin against chemical and natural toxicants by targeting NF- κ B pathway. **2022**, 48, 744-762 2
- 134 Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy. **2022**, 22, 0
- 133 A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial. 1
- 132 A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes. Volume 14, 199-210
- 131 Endokrine Therapien beim Mammakarzinom. **2022**, 111, 550-556
- 130 Tamoxifen-resistant breast cancer cells exhibit reactivity with Wisteria floribunda agglutinin. **2022**, 17, e0273513
- 129 Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study. 1
- 128 Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer. **2022**, 5, e2225345 0
- 127 The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience. **2022**,
- 126 Effects of Cimicifuga racemosa (L.) Nutt on sexual function in women receiving tamoxifen for breast cancer. 1-5
- 125 Acupuncture for hot flashes in hormone receptor-positive breast cancer, a coordinated multinational study: Rationale and design of the study protocol. **2022**, 106885
- 124 Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. 107815522211197
- 123 Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?. **2022**, 110, 102445 1
- 122 Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. **2022**, 175, 169-179 0
- 121 Omission of Radiation. **2022**, 347-358 0
- 120 Target Volume Definition and Delineation Boost/PBI/SIB. **2022**, 139-150 0
- 119 Intensity Modulated Radiotherapy and Volumetric Modulated Arc Therapy in the Treatment of Breast Cancer: An Updated Review. 25, 0

118	High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes. 2022 , 8,	1
117	Androgen receptor in breast cancer: The BW questions. 13,	0
116	Endocrine therapy resistance: what we know and future directions. 480-496	0
115	Survival Benefit of Adjuvant Endocrine Therapy for Hormone Receptor Low-Positive Breast Cancer: A Propensity Score-Weighted Analysis.	0
114	Five decades of progress in surgical oncology: Breast. 2022 , 126, 852-859	0
113	Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients.	1
112	Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer. 2022 , 14, 4289	2
111	Analysing breast cancer survivors' acceptance profiles for using an electronic pillbox connected to a smartphone application using Seintinelles, a French community-based research tool. 13,	0
110	Influence of Tamoxifen on Different Biological Pathways in Tumorigenesis and Transformation in Adipose-Derived Stem Cells, Mammary Cells and Mammary Carcinoma Cell Lines An In Vitro Study. 2022 , 11, 2733	0
109	Person-centred support programme (RESPECT intervention) for women with breast cancer treated with endocrine therapy: a feasibility study. 2022 , 12, e060946	0
108	Comparison of Clinical, Histopathological, and Survival Outcomes of Pure and Mixed Mucinous Breast Carcinoma.	0
107	Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy A Review Study. 2022 , 18, 292-298	0
106	Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ER-positive breast cancer. 2022 , 12,	1
105	The Landmark Series Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women.	0
104	Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. 2022 , 176, 58-69	0
103	Five Cases of Breast Cancer-Related Therapy Complications Successfully Treated with Kampo Medicine. 2021 , 72, 264-274	0
102	Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. 12,	0
101	A CAF-Fueled TIMP-1/CD63/ITGB1/STAT3 Feedback Loop Promotes Migration and Growth of Breast Cancer Cells. 2022 , 14, 4983	1

- 100 Multi-compartment tumor organoids. **2022**, ○
- 99 The relationship between medication adherence and illness perception in breast cancer patients with adjuvant endocrine therapy: beliefs about medicines as mediators. ○
- 98 Adherence to adjuvant endocrine therapy among White British and ethnic minority breast cancer survivors in the United Kingdom. ○
- 97 The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. **2022**, 22, ○
- 96 State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. **2022**, ○
- 95 Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer. **2022**, 23, 12290 1
- 94 Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study. ○
- 93 Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier. **2022**, 14, 5132 ○
- 92 Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials. 12, ○
- 91 Sonographic and Hysteroscopic Surveillance in Women with Breast Cancer Treated with Tamoxifen: A Retrospective Study. **2022**, 20, ○
- 90 You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?. ○
- 89 Neoplasms of the Breast. 1-62 ○
- 88 Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs. ○
- 87 Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer. ○
- 86 Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score[®] Test?. **2022**, 12, 2730 ○
- 85 Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Publish Ahead of Print, ○
- 84 Current Standard Clinical Predictive Markers. **2022**, 873-894 ○
- 83 Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer. **2023**, 37, 89-102 ○

82	Photodynamic therapy with zinc phthalocyanine enhances the anti-cancer effect of tamoxifen in breast cancer cell line: Promising combination treatment against triple-negative breast cancer?. 2023 , 41, 103212	0
81	Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study. 2022 , 2022, 1-11	1
80	Association of hormone receptor status with cardiovascular disease mortality in 399,209 patients with stage I to III breast cancer: A population-based study. 2022 , 101, e31911	0
79	Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.	1
78	Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study. 2022 , 24, 361-367	0
77	Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer. 2022 , 5, e2243951	1
76	Does the toxicity of endocrine therapy persist into long-term survivorship?: Patient-reported outcome results from a follow-up study beyond a 10-year-survival.	1
75	Radiation in Early-Stage Breast Cancer: Moving beyond an All or Nothing Approach. 2023 , 30, 184-195	0
74	A prospective cohort study of clinical characteristics and outcome of Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer.	0
73	Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.	0
72	Tumor characteristics, therapy, and prognosis in young breast cancer patients ≤5 years.	0
71	Obesity as a Risk Factor for Breast Cancer—the Role of miRNA. 2022 , 23, 15683	0
70	Identifying the predictors of adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status.	0
69	Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer. 2022 , 22,	2
68	A cost-consequences analysis of the SAFE trial: a comparative, effectiveness trial evaluating high-versus low-supervision of an exercise intervention for women with breast cancer.	0
67	AKTIP loss is enriched in ER ⁺ positive breast cancer for tumorigenesis and confers endocrine resistance. 2022 , 41, 111821	0
66	The importance of long-term follow up of participants in clinical trials.	0
65	A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. 2022 , 13,	1

- 64 Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion. 1-3 ○
- 63 Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature. **2022**, 16, ○
- 62 NOHA: A Promising Biomarker for Determining Estrogen Receptor Status Among Patients With Breast Cancer in Resource-Constrained Settings. **2022**, ○
- 61 Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. 1
- 60 Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. **2022**, 14, 175883592211417 ○
- 59 Breast Cancer. **2022**, 133-181 ○
- 58 Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy. ○
- 57 The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer. 12, ○
- 56 Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR-mediated epigenetic suppression on VGLL4 by DNMT1. ○
- 55 Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women. ○
- 54 Breast cancer cells interact with tumor-derived extracellular matrix in a molecular subtype-specific manner. **2023**, 213301 ○
- 53 Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023. **2023**, 35, 67-72 ○
- 52 Harmine suppresses the malignant phenotypes and PI3K activity in breast cancer. Publish Ahead of Print, ○
- 51 Prevention of Osteoporosis in Patients With Breast Cancer Treated With Aromatase Inhibitor Combined With Calcium/Vitamin D Supplements. **2022**, 10, 61-68 ○
- 50 Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone vs. Endocrine Therapy Alone or Combined Treatment for Low-Risk ER-positive Early-Stage Breast Cancer in Women Age 65 and Older. **2022**, ○
- 49 Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?. **2023**, 30, 392-400 ○
- 48 Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study. **2022**, 6, e37144 ○
- 47 MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 Early Breast Cancer Patients. ○

- 46 Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. Volume 16, 49-64
- 45 Side Effects and Its Management in Adjuvant Endocrine Therapy for Breast Cancer: A Matter of Communication and Counseling. **2023**, 17, 117822342211454
- 44 Protein Cancer Biomarkers. **2023**, 148-179
- 43 Use of endocrine therapy for estrogen receptor-positive breast cancer among American Indians and Alaska natives.
- 42 Revisiting primary endocrine therapy versus surgery in older women with breast cancer: meta-analysis.
- 41 Co-development of a text messaging intervention to support adherence to adjuvant endocrine therapy in women with breast cancer: A mixed-methods approach (Preprint).
- 40 Patterns and Longitudinal Changes in the Practice of Breast Cancer Radiotherapy in Korea: Korean Radiation Oncology Group 22-01. 26,
- 39 Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status. **2023**, 129, 1173-1182
- 38 Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer. **2023**,
- 37 Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale. **2023**, 160, 114369
- 36 Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2IA3 EGFR-Mutated NSCLC: ADAURA2. **2023**,
- 35 The prognostic value and response to immunotherapy of immunogenic cell death-associated genes in breast cancer. 13,
- 34 Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk. **2023**, 198, 361-368
- 33 Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?. **2023**, 42, 1-4
- 32 Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea. **2023**, 13, 792
- 31 BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer.
- 30 Single progesterone receptor-positive phenotype has the similar clinicopathological features and outcome as triple-negative subtype in metastatic breast cancer. 13,
- 29 Exploration of prognostic genes and risk signature in breast cancer patients based on RNA binding proteins associated with ferroptosis. 14,

- 28 ER/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor. **2023**, 30, 436-452 ○
- 27 Advances in Breast Cancer Screening: Precision, Imaging, and Harms. **2023**, 1-27 ○
- 26 Evaluation of the relationships between ER, PR, c-erbB2, Ki67, E-Cadherin expressions, Nottingham histological grade and some clinical parameters in breast carcinomas. ○
- 25 Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence. **2023**, 31, ○
- 24 A case of BRCA2-pathogenic variant breast cancer with metachronous endometrial cancer and pancreatic cancer: Case report and review of literature. ○
- 23 Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers. **2023**, 24, 5474 ○
- 22 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32 ○
- 21 Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta-analysis. **2023**, 6, ○
- 20 Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer. **2023**, 24, 5583 ○
- 19 Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy. **2023**, 9, ○
- 18 Hormones and antihormones in cancer chemotherapy. **2023**, 589-613 ○
- 17 Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer: A Retrospective Cohort Study of 161,492 Patients in Germany. **2023**, 15, 1847 ○
- 16 Recent Trends in Biosensing and Diagnostic Methods for Novel Cancer Biomarkers. **2023**, 13, 398 ○
- 15 Relationship between tumor microbiota transcriptional activity and gene expression in breast cancer. **2023**, 23, ○
- 14 Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study. ○
- 13 Acceptability, fidelity and trial experience of four intervention components to support medication adherence in women with breast cancer: A process evaluation protocol for a pilot fractional factorial trial. 3, 3 ○
- 12 Compliance to adjuvant endocrine therapy and survival in breast cancer patients.. **2023**, 35, 100704 ○
- 11 Fluorescent tamoxifen derivatives as biophotonic probes for the study of human breast cancer and estrogen-receptor directed photosensitizers. **2023**, 138, 113736 ○

- 10 Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update. **2023**, 16, 550
- 9 Investigation of anti-breast cancer potential of a Coral-derived heterocyclic molecule Capillobenzofuranol by inhibiting Estrogen Receptor- β
- 8 Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.
- 7 SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer. **2023**, 15, 2271
- 6 Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial. **2023**, 25,
- 5 Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. **2023**, 12, 1156
- 4 Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors. **2023**, 31,
- 3 Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. **2023**, 13, e070972
- 2 Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.
- 1 Breast cancer-related lymphedema and recurrence of breast cancer: Protocol for a prospective cohort study in China. **2023**, 18, e0285772